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ABSTRACT 
Introduction:  
Obesity has reached epidemic proportions worldwide and is currently a serious health problem. 
It is associated with metabolic abnormalities, oxidative stress, hypertension, insulin resistance 
and an increased disposition for the development of cardiovascular disease. 
Elucidation of the pathophysiological mechanisms underlying obesity and its relationship with 
metabolic and cardiovascular diseases is essential for prevention and management of these 
disorders. Melatonin, the pineal gland hormone, is a powerful antioxidant and has been shown 
to protect the myocardium against ischaemia/reperfusion (I/R) injury. Long- as well as short-
term melatonin treatment also reversed several of the harmful effects of obesity in an animal 
model of hyperphagia-induced obesity (DIO). However, its effects on myocardial I/R injury 
and intracellular signalling in obesity induced by a high fat diet (HFD) are still unknown.  
Aims of study: 
(i) To evaluate the ability of a high fat diet (HFD) to induce obesity in rats. Apart from 
evaluating its effects on the biometric parameters and resistance to ischaemia/reperfusion 
injury (as indicated by infarct size in regional ischaemia and functional recovery after 
global ischaemia), special attention will be given on the interplay between adiponectin, 
AMPK, leptin, and FFA in this model.  
(ii) To evaluate the effect of daily oral administration of melatonin to rats on the HFD as well 
as their littermate controls, on the parameters listed above as well as on the development 
of obesity. In this study melatonin will be administered from the onset of the feeding of 
the high fat diet. 
Methods: 
Male Wistar rats were divided into 4 groups: (i) control rats (receiving normal rat chow) (C); 
(ii) control rats receiving melatonin (CM); (iii) obese rats (receiving HFD) (HFD); (iv) obese 
rats receiving melatonin (HM). Animals were kept on the diet for 16 weeks and melatonin 
treatment (10mg/kg/day, added to the drinking water) started at the onset of the feeding. 
Following feeding and treatment, the animals were grouped into fasted/ non-fasted of which 
biometric parameters were recorded and blood collected at the time of sacrifice for metabolic 
and biochemical assays. Hearts were perfused in the working mode for evaluation of 
myocardial function and infarct size determination after exposure to 35min regional 
ischaemia/60min reperfusion.  For study of intracellular signaling, hearts were perfused in the 
working mode, subjected to 20min global ischaemia/10min reperfusion and freeze-clamped for 
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Western blotting. Plasma leptin, adiponectin, free fatty acid, triglycerides, total cholesterol, 
 phospholipids, conjugated dienes and thiobarbituric reactive substances (TBARS) levels were 
determined. Several kinases were investigated including, the RISK (reperfusion injury salvage 
kinase) (PKB/Akt and ERK p44/42) and SAFE (survivor activating factor enhancement) 
(STAT-3) pathways, AMPK and JNK under baseline conditions or following 10 min 
reperfusion. In addition, expression of UCP-3 and PGC1-α was determined. 
Results: 
Significant increases in body weight, visceral fat, blood glucose, insulin, HOMA index and 
leptin and a reduction in adiponectin levels were observed in the fasted high fat diet (HFD) 
group when compared with controls (C). Significant increases in free fatty acid and triglyceride 
levels were also noted the HFD group while other serum lipid parameters, including TBARS, 
remained unchanged. No differences in functional recovery during reperfusion or infarct size 
after exposure to 35 min regional ischaemia, as well as functional recovery during reperfusion 
after 20 min global ischaemia were observed between the control and HFD groups. Baseline 
and 10 min reperfusion data were similar for the RISK and SAFE pathway kinases for the 
control vs HFD groups. The HFD also had no effect on the expression and phosphorylation of 
myocardial AMPK and JNK, as well as on the expression of UCP-3 and PGC1-α, when 
compared to the controls. Treatment with melatonin significantly reduced body weight, visceral 
fat, blood glucose, HOMA index and serum leptin levels in HFD treated groups, while having 
no effect on the lipid profile. Although melatonin significantly reduced infarct size in both 
control [% of area at risk: 20.59 ± 2.29 (CM) vs 38.08 ± 2.77 (C)] and high-fat diet groups [% 
of area at risk: 11.43 ± 2.94 (HM) vs 38.06 ± 3.59 (H)], it was without effect on myocardial 
functional recovery during reperfusion. Melatonin had no effect on the intracellular signaling 
pathways studied. 
Conclusions:  
The HFD proved to be a useful model of diet-induced obesity with a more pronounced impact 
on biometric and metabolic changes compared to the DIO model. Long-term melatonin 
treatment successfully prevented the development of metabolic abnormalities associated with 
the high fat diet and obesity as well as significantly reduced myocardial infarct size. The 
mechanisms involved in melatonin-induced cardioprotection in obesity have not been fully 
elucidated in this study and require further investigation. However, the anti-obesogenic and 
cardioprotective properties of melatonin were very significant indeed and support the 
suggestion of this hormone as a potential tool in the treatment of obesity and associated 
cardiovascular complications.  
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ABSTRAK 
Inleiding: Vetsug (obesiteit) het wêreldwyd epidemiese afmetings aangeneem en word tans as 
‘n ‘n ernstige gesondheidsprobleem beskou.  Vetsug word geassosieer met metaboliese 
afwykings, oksidatiewe stres, hipertensie, insulienweerstandigheid en is‘n belangrike 
risikofaktor vir die ontwikkeling van kardiovaskulêre siekte. Ten spyte hiervan, het onlangse 
studies ‘n gunstige effek van vetsug op die uitkomste van miokardiale infarksie in pasiënte 
gerapporteer, die sg obesiteitsparadoks. Kennis van die patofisiologiese meganismes 
onderliggend aan vetsug en die ontstaan van metaboliese afwykinge en hartsiekte is 
noodsaaklik vir die voorkoming en behandeling van hierdie toestande. Melatonien, die 
hormoon afgeskei deur die pineaalklier, is ‘n kragtige antioksidant en vry radikaal opruimer. 
Dit is voorheen aangetoon dat dit die hart teen iskemie/herperfusie (I/H) besering kan beskerm 
en sommige van die skadelike gevolge van vetsug in diermodelle kan omkeer. Die effek van 
melatonien op miokardiale I/H besering en intrasellulêre seintransduksie prosesse in vetsug 
geïduseer deur ‘n hoë vet dieet is egter nog onbekend. 
Doelstellings: 
(i) Die ontwikkeling en karakterisering van ‘n nuwe model van vetsug en insulien- 
weerstandigheid geïnduseer deur 'n hoë vet dieet (HVD) en die evaluering van die effek 
daarvan op miokardiale I/H besering en die gepaardgaande intrasellulêre 
seintransduksieprosesse; 
(ii) Bepaling van die effek van daaglikse toediening van melatonien aan rotte op die HVD 
sowel as aan kontroles op ‘n standard dieet, op die ontwikkeling van dieet-geïnduseerde 
metaboliese veranderinge, miokardiale infarktgrootte en funksionele herstel na koronêre arterie 
afbinding, sowel as intrasellulêre seintransduksie.  
Metodiek: Vier groepe van manlike Wistar rotte is bestudeer: (i) kontrole rotte (op‘n standaard 
dieet) (K); (ii) kontrole rotte op ‘n standard dieet plus melatonien (KM); (iii) dieetrotte (op‘n 
HVD); (iv) HVD rotte wat melatonien ontvang (HM). Die HVD en melatonien (10mg/kg/dag 
in die drinkwater) is vir 16 weke toegedien. Na die periode van behandeling, is die diere in 
vastende en nie-vastende groepe verdeel, die  biometriese parameters genoteer en  
bloedmonsters vir metaboliese en biochemiese bepalings versamel, tydens verwydering van 
die harte. Harte is geperfuseer volgens die werkhartmodel vir bepaling van miokardiale funksie 
en infarktgrootte na blootstelling aan 35min streeksiskemie. Vir evaluering van intrasellulêre  
seintransduksie, is geperfuseerde werkende rotharte blootgestel aan 15min globale iskemie/10 
min herperfusie en gevriesklamp vir latere analises volgens die Western kladtegniek.hart.  
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Serum leptien, adiponektien, vryvetsure, trigliseried, totale cholesterol, fosfolipiede, 
gekonjugeerde diene en tiobarbituursuur reaktiewe stowwe (TBARS) is bepaal. Met gebruik 
van Western kladtegniek, is die aktivering en/of uitdrukking van die RISK (PKB/ Akt en ERK 
p44/42) en SAFE (STAT-3) seintransduksiepaaie, AMPK, JNK, UCP-3 en PGC1-α, onder 
basislyn toestande of na 10 min herperfusie bestudeer. 
Resultate:‘n Beduidende toename in liggaamsgewig, visserale vet, die HOMA indeks, insulien 
en leptien vlakke is in die HVD groep waargeneem vergeleke met die kontrole (K) rotte.  
Adiponektien vlakke was laer in die HVD groep.  Die HVD groep is ook gekenmerk deur ‘n 
beduidende styging in serum vryvetsuur en trigliseried vlakke, terwyl die ander lipied 
parameters, insluitende die TBARS vlakke, onveranderd was. Infarktgrootte en funksionele 
herstel tydens herperfusie na blootstelling aan 35 min streeksiskemie, asook funksionele herstel 
tydens herperfusie na 20 min globale iskemie het nie verskil tussen harte van die kontrole en 
HVD rotte nie.  Aktivering van PKB/Akt, ERK p44/p42, STAT3, AMPK en JNK by basislyn 
en na 10 min herperfusie was soortgelyk in die kontrole en HFD groepe. Die HVD het ook 
geen effek op die uitdrukking van UCP-3 en PGC1-α in vergelyking met die kontrole gehad 
nie. Behandeling met melatonien het die liggaamsgewig, visserale vet, bloedglukose, HOMA 
indeks en serum leptien vlakke in die HVD groepe statisties beduidend verlaag, terwyl dit geen 
invloed op die lipiedprofiel gehad het nie. Melatonien behandeling het die miokardiale 
infarktgrootte beduidend en tot dieselfde mate verminder in beide kontrole [20.59 ± 2.29 (KM) 
vs 38.08 ± 2.77% (K)] en HVD groepe [11.43 ± 2.94 (HM) vs 38.06 ± 3.59% (HVD)]. Geen 
verskille is egter tussen die funksionele herstel gedurende herperfusie van die behandelde en 
onbehandelde kontrole en HVD groepe waargeneem nie. Melatonien het ook geen uitwerking 
op die intrasellulêre seintransduksiepaaie gehad nie. 
Gevolgtrekkings: Die resultate het getoon dat die HFD 'n goeie model van dieet-
geïnduseerde vetsug en insulien weerstandigheid ontlok, met 'n meer uitgesproke impak op 
biometriese en metaboliese veranderinge as die voorheen gebruikte hoë-sukrose dieet. 
Langtermyn melatonien- behandeling het die ontwikkeling van metaboliese abnormaliteite 
geassosieer met die HVD, voorkom, asook miokardiale infarktgrootte na koronêre afbinding 
beduidend verminder. Die meganismes betrokke in melatonien-geïnduseerde miokardiale 
beskerming moet egter in meer detail ondersoek word. Die resultate verkry steun die voorstel 
dat melatonientoediening voordelig sal wees in die behandeling van vetsug en sy 
kardiovaskulêre komplikasies.                  
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H2O2: Hydrogen peroxide  STAT-3: Signal transducer and activator of transcription 3 
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HOMA: Homeostasis model assessment TZD: Thiazolidinediones  
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IFS: Infarct size WHO: World Health Organisation 
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CHAPTER 1 
LITERATURE REVIEW 
 
1. OBESITY AND CARDIOVASCULAR DISEASE 
Introduction 
 
In the past two decades, obesity has reached epidemic proportions worldwide (for a review see 
Cao, 2014). Defined as having a body mass index (BMI) of or greater than 30 kg/m2 (Jahangir 
et al., 2014), obesity is a condition characterized by an imbalance between food intake and 
energy expenditure resulting in adipose tissue expansion (Yingzhong et al. 2006) and increased 
health risk (Etelson et al., 2003). 
 
Obesity poses a risk for several disorders such as, hypertension, insulin resistance and fatty 
liver disease, with an increased predisposition for the development of cardiovascular disease, 
type 2 diabetes mellitus (Emanuela et al., 2012; for a review see Cao, 2014) and cancer (Haslam 
et al., 2006). Mounting evidence have also linked obesity to obstructive sleep apnoea, 
osteoarthritis (Haslam & James, 2005) and chronic kidney disease (Ruan & Guan, 2009). 
 
Although obesity has long been associated with serious adverse health conditions, in recent 
years, along with body weight management, it is rapidly becoming the center of attention for 
public health experts (Kopelman, 2000; James, 2008). According to the World Health 
Organization (WHO), globally 600 million adults (18years and older) are obese and 42 million 
children are overweight/obese, with escalating obesity rates in both adults and children (Wang 
et al., 2008).
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Elucidation of the pathophysiological mechanisms underlying obesity and its relationship with 
metabolic and cardiovascular diseases are essential for prevention and management of these 
disorders (Ohashi et al. 2014).  
Obesity is a multifactorial disease and the mechanisms underpinning the development thereof 
have been associated with dysfunction of adipocytokine pathways (Vazquez-Vela et al., 2008) 
while its comorbidities, such as increased fat accumulation, lipotoxicity, increased oxidative 
stress and insulin resistance, have been suggested as possible mechanisms linking it to 
increased cardiovascular risk (For a review see Bluher, 2012).  
In particular, obesity is a major risk factor for the development of cardiovascular disease and 
heart failure, causing a reduction in life expectancy and quality of life (see for example Diercks 
et al., 2006; Mahamat et al., 2003; Chase et al., 2014). Obese patients with cardiovascular 
disease are also more likely to develop acute coronary syndromes, likely because of 
concomitant comorbidities that tend to cluster with obesity, which include hypertension, 
diabetes mellitus and hyperlipidemia, as mentioned above (Wolk et al., 2003). Thus, 
elucidation of the pathophysiological mechanisms underlying obesity and its relationship with 
metabolic and cardiovascular diseases is essential for prevention and management of these 
disorders (Ohashi et al. 2014).  
 
In view of the above, the first sections of the literature survey will focus on the physiological 
role of adipose tissue, the changes induced by obesity as well as the possible underlying 
mechanisms in cardiovascular disease and associated metabolic abnormalities.  
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1.1 Physiological role of adipose tissue and adipocytes 
 
It is well-established that adipose tissue (AT), being the most widespread tissue in humans, 
plays a dynamic role in physiological processes occurring throughout the body. Adipose tissue 
(subcutaneous and visceral fat) is known to cushion and insulate the body, but more importantly 
to store energy, specifically in white adipose tissue (WAT) depots (Golan et al., 2012; Haas et 
al., 2012). 
Its main constituent, adipocytes, is considered to be a corner stone in the homeostatic control 
of whole body metabolism (Ali et al. 2013).  Adipocytes store triglycerides (Ntambi & Young-
Cheul, 2000) derived from the diet and accounts for the majority of fat stored in the body. 
Lipolysis of adipose tissue triglycerides is responsible for the release of free fatty acids (FFA), 
the principal lipid fuel present in the circulation. Insulin is the main regulator of adipocyte fat 
content, enhancing FFA uptake and triglyceride synthesis (for a review see Hajer et al. 2008). 
In contrast to WAT, brown adipose tissue (BAT) is specialized in generating heat in response 
to cold or diet (nonshivering thermogenesis) rather than oxidizing fatty acids (Jimenez-Aranda 
et al. 2013).  
Besides the classical function of storing fat, numerous biologically active substances 
(adipocytokines/adipokines) are secreted by adipocytes (Greenberg & Obin, 2006; Jensen et 
al., 2006). 
Thus fat is considered to be a major endocrine organ with profound effects on the regulation 
of normal body processes (Ali et al. 2013) and is increasingly being recognized as an important 
role player in the development of obesity (Kershaw & Flier, 2004; Fonseca-Alaniz et al., 2006; 
for a review see Khan & Joseph et al., 2014), which will be discussed below.  
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1.2 Adipose tissue-derived secretions: adipokines 
 
Adipose tissue plays a central role in metabolic alterations (insulin resistance, type 2 diabetes, 
amongst others) triggered by lipid over-accumulation, leading to disordered adipocyte function 
(For a review see Schuster, 2010; El Akoum et al., 2011).  
Given the importance of adipocytes and adipose tissue in obesity and obesity-related diseases 
(Rosen & Spiegelman, 2006), adipokines have been studied extensively as they are known to 
regulate pivotal aspects of metabolism (Pajvani et al., 2003; Gunawardana, 2014), reflect 
adipose tissue function and have noteworthy effects on the brain, muscle, liver and pancreas 
(For a review see Bluher, 2012; Trujillo & Scherer, 2006). 
It has been well reviewed that increased adiposity leads to adipose tissue dysfunction mirrored 
by impaired adipokine secretion and activation of pro-inflammatory signaling (Bastard et al., 
2006; Wellen & Hotamisligil, 2005), suggesting a potential link for obesity and inflammation, 
insulin resistance and adverse cardiovascular outcomes (Flehmig et al., 2014; Dunmore & 
Brown, 2013; Wellen & Hotamisligil, 2005). 
 
The adipose tissue-derived hormone, leptin, surfaced as a ‘central player’ in the cloning of 
genes involved in body weight control (Zhang et al., 1994; for a review see Yingzhong et al., 
2006), which further stimulated the discovery of new adipose tissue derived signals (Haluzik 
et al., 2004; Gomez et al.,2009). Among the many putative molecules, interleukin-6 (IL-6) and 
tumor necrosis factor alpha (TNF-α) have been identified to play a role in the inflammatory 
response. While adipokines such as omentin, vaspin, chemerin, resistin, and fatty acid binding 
protein 4 have been associated with insulin resistance (For reviews see Bluher, 2012; Haas et 
al. 2012; Haluzik et al. 2004), adiponectin has been shown to positively correlate with insulin 
sensitivity and supplementation thereof attenuates insulin resistance (Yamauchi et al., 2002).  
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Research has focused on the clinical relevance of adipokines as markers or predictors of obesity 
related diseases and as potential therapeutic tools or targets thereof (For review see Bakhai, 
2008; Bluher, 2012). The importance of adipokines in regulating normal body processes, such 
as energy metabolism, appetite control (For a review see Fisman & Tenenbaum, 2014), insulin 
sensitivity (For a review see Bluher, 2012), inflammation and cardiac function (Flehmig et al., 
2014) have been highlighted. Conversely, a role for adipokines in the pathophysiology of 
several metabolic diseases has been established (Bluher, 2009; for a review see Fisman & 
Tenenbaum, 2014). The respective roles of leptin and adiponectin in health and obesity are 
summarized below. 
 
 
1.3 Leptin 
Leptin, a 16kDa hormone, was first identified by Zhang and coworkers in a mouse model of 
obesity (Zhuang et al., 2009). It is abundantly expressed in adipose tissue, specifically 
adipocytes, and is a key factor in the regulation of energy homeostasis (Jung & Choi, 2014).  
It is encoded by the obese (ob) gene and is known to inhibit appetite/food intake and stimulate 
energy expenditure (Fortuno et al., 2003) via three neurons in the hypothalamus, neuropeptide 
Y (NPY), γ-aminobutyric acid (GABA), and pro-opiomelanocortin (POMC) (Morton et al., 
2005). 
 Although leptin’s actions are predominantly exerted via the hypothalamus, it also directly 
affects peripheral tissues (Schwartz et al., 2000). In vivo studies have shown that leptin 
improves insulin sensitivity (Wang et al., 1999; Kahn & Flier, 2000), possibly by preventing 
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fat deposition in the liver and skeletal muscle and directly enhances muscle fatty acid oxidation 
(in vitro) by activating AMP-activated protein kinase (AMPK) (Muoio, 1997).  
It is well-established that circulating leptin levels and its mRNA expression are elevated in 
obese subjects (Kim-Motoyama et al., 1997). A phenomenon known as leptin resistance occurs 
as a result of excessive food intake, impairing leptin’s actions (Lin et al., 2000) in leptin-
responsive areas in the brain (Jequier, 2002). Strong associations between leptin resistance and 
endothelial dysfunction, heart-failure, atherosclerosis and hypertension, among many other 
related metabolic disorders, have been made (for a review see Gomez et al., 2009). The anti-
diabetic effect of leptin is mediated by activation of the (PI3K)/Akt pathway that stimulates 
insulin sensitivity in peripheral tissues (Morton, et al. 2005).  
Growing evidence suggests that leptin may contribute to the development of cardiac 
dysfunction (for reviews see Karbowska & Kochan, 2012; Hou & Luo, 2011). In a large 
prospective study leptin has been shown to an independent risk factor for coronary heart 
disease. In animal studies chronic leptin infusion increased heart rate and blood pressure and it 
has been demonstrated that circulating leptin levels are elevated in patients with heart failure. 
Moreover, a role for this hormone in mediating myocardial hypertrophy has been suggested. 
Findings thus far have suggested that leptin acting directly of through the sympathetic nervous 
system may have adverse effects on cardiac structure and function and that chronic 
hyperleptinemia may greatly increase the risk of cardiac disorders. 
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1.4 Adiponectin   
Adiponectin or adipocyte-complement related protein of 30 kDa (Acrp30) is present in high 
levels in human plasma relative to other hormones (for a review see Diez & Iglesias, 2003), 
with concentrations ranging from 5 to 30mg/L, accounting for more or less 0.01% of total 
plasma protein (Arita et al., 1999). Due to the remarkable effects of adiponectin on various 
systems in the body, much attention has been given to the receptors (AdipoR1 and AdipoR2) 
through which it acts (Yamauchi et al., 2003). 
Adiponectin differs from other adipokines in that it is secreted solely by adipose tissue (Maeda 
et al., 1996), and found at reduced levels in the presence of obesity (Arita et al., 1999), type 2 
diabetes and heart disease (For a review see Lee & Kwak, 2014). It is well established that 
plasma adiponectin levels are negatively associated with the accumulation of body fat, 
particularly visceral fat (Matsuzawa et al., 2004).  
 Adiponectin has diverse functions ranging from aiding in lipid and glucose metabolism to 
immune cell function. It exerts direct actions on the liver, skeletal muscle (Berg et al., 2001) 
and cardiovascular system (Ouchi et al., 2006) and may possess both protective and 
ameliorating effects in many metabolic diseases, with its insulin sensitizing effects being one 
of its key properties (For reviews see Berg et al., 2002; Trujillo & Scherer, 2006).  
Being the most abundantly secreted adipocyte derivative, adiponectin has been implicated in 
the interrelationship between obesity, insulin resistance and inflammation (Silva et al., 2014; 
for a review see Fisman & Tenenbaum, 2014). 
Clinical studies indicate a close association of low adiponectin levels (hypoadiponectinemia) 
with endothelial dysfunction and insulin resistance (Kadowaki et al., 2007; Matsuzawa et al., 
2004; Gomez et al., 2009). Hypoadiponectinemia also positively correlates with elevated levels 
of the pro-inflammatory cytokine, tumor necrosis factor alpha (TNFα) in obesity (Hector et al., 
2007). Long-term administration of globular adiponectin to rats on a high-fat diet enhanced 
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insulin signaling and lipid storage in adipose tissue, resulting in improvements of the metabolic 
profile (Matafome et al., 2014). Increased fatty acid oxidation and inhibition of hepatic glucose 
production have been reported as the key mechanisms through which adiponectin enhance 
insulin sensitivity (Kadowaki et al., 2007; Silva et al., 2014). 
 
Several studies investigated the role of adiponectin in cardiac diseases associated with obesity 
(Okamoto, 2011). It is well known that cardiovascular risk factors such as obesity, dyslipidemia 
and increased blood pressure are associated with low levels of adiponectin, suggesting a link 
between hypoadiponectinemia and cardiovascular disease (Arita et al., 1999; Matsuzawa et al., 
2004). Associations of hypoadiponectinemia have further been made with cardiac hypertrophy 
(Okamoto, 2011) and coronary artery disease (Ouchi et al., 1999; Hotta et al., 2001). 
 
 The significance of adiponectin in the response of the heart to ischaemia/reperfusion was 
illustrated in a study by Shibata et al. (2005) who showed increases in myocardial infarct size 
and apoptosis, as well as elevated expression of TNF-α, in adiponectin knock-out mice. 
Pretreatments with adiponectin of these knock-out mice reduced the infarct size and apoptosis 
after ischemia/reperfusion, suggesting a cardioprotective role for adiponectin in cardiac 
myocytes (Shibata et al., 2005).  
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1.5 DEVELOPMENT OF INSULIN RESISTANCE AND OBESITY 
Obese individuals tend to be both insulin resistant and at increased risk to develop 
cardiovascular disease. However, a large epidemiological study showed although 36% of 
individuals in the most insulin-resistant group were obese, not all overweight/obese individuals 
are insulin resistant and not all insulin resistant individuals are overweight/obese (McLaughlin 
et al., 2004; Reaven 2011). 
 
1.5.1 Pathophysiology of insulin resistance  
 
Insulin is a pleiotropic hormone produced in the pancreatic β-cells. It has effects on muscle, 
liver and adipose tissue thereby influencing metabolism and various cellular processes 
throughout the body (Jellinger, 2007). Insulin orchestrates the regulation of glucose 
homeostasis through promoting glucose uptake in peripheral tissue, such as muscle (skeletal 
and heart), fat (brown and white), and in suppressing hepatic glucose production (Benito, 
2011). 
Apart from insulin’s effect on nutrient metabolism, it is also involved in protein synthesis, 
growth, generation of new mitochondria (biogenesis), autophagy, proliferation and 
differentiation (For a review see Bunner et al., 2014).  
 
Insulin resistance is a generalized metabolic disorder characterized by inefficient insulin 
function or decreased cellular sensitivity to insulin in skeletal muscle, liver and adipocytes 
(Haag & Dipenaar, 2005). Growing evidence support the notion that increased circulating FFA 
levels play an important role in the development of insulin resistance and deterioration of β-
cell function due to hyperglycemia (Shulman, 1999; Evans et al., 2003). Insulin resistance 
hinders the normal actions of insulin such as increased muscle and cellular glucose uptake, 
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glycogen synthesis and reduction in hepatic glucose production (Petersen & Shulman, 2002; 
Haag & Dipenaar, 2005). 
Insulin resistance manifests differently in different tissues. For example, it can originate in 
adipose tissue, where it results in increased lipolysis, thereby releasing glycerol and fatty acids 
(FFA) into the circulation. In the liver, insulin resistance is manifested by impairing the ability 
of insulin to suppress glucose production thereby raising blood glucose levels (Kahn & Flier, 
2000; Manrique et al., 2014; Muniyappa et al., 2008).  
 
Insulin resistance can be measured by a number of approaches, including the Homeostatic 
Model Assessment of Insulin Resistance (HOMA-IR) (Matthews et al., 1985), the quantitative 
insulin sensitivity check (QUICK) index (Katz et al., 2000), and the gold standard, 
hyperinsulinemic-euglycemic clamp test (DeFronzo et al., 1979). 
The nuclear receptor, peroxisome proliferator-activated receptor λ, important in lipid 
metabolism, has been identified as an important target of insulin sensitizing drugs, such as the 
thiazolidinediones (TZDs), to counteract insulin resistance and type 2 diabetes (For a review 
see Bunner et al., 2014).  TZDs promote differentiation of preadipocytes into white adipocytes 
and are assumed to redirect FFA away from skeletal muscle towards adipose tissue (the so-
called lipid steal hypothesis). The TZDs are also implicated in positively influencing insulin 
resistance by decreasing the expression of TNFα, IL-1 and resistin while increasing the 
adiponectin production (Haas et al., 2012).  
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1.5.2 Mechanisms of obesity-induced insulin resistance 
 
1.5.2.1 Insulin signaling in insulin sensitive and resistant tissue  
 
Binding of insulin to its receptor (IR) triggers its phosphorylation and activation via an intrinsic 
kinase activity, leading to tyrosine phosphorylation of the insulin receptor substrate (IRS) 
proteins 1 to 4 (Saltiel & Kahn, 2001). 
Normal insulin signaling following stimulation of the insulin receptor (IR) is mediated by two 
different pathways: the phosphatidylinositol-3-OH kinase pathway (PI3K pathway) which is 
predominant in metabolic tissue and a second, growth factor-like promitotic pathway namely 
mitogen-activated protein kinase (MAPK) (Muniyappa & Sowers, 2013; Manrique et al., 
2014).  
Tyrosine phosphorylation of insulin receptors (1 to 4) initiates the PI3K pathway to produce 
phosphatidylinositol-3,4,5-triphosphate (PIP3), and its increased production results in 
activation of PKB/Akt via phosphoinositide-dependent kinase 1 (PDK1) activation (Shulman 
et al., 1999) which in turn activates PKC (ζ and λ) (Bertrand et al., 2008). Other downstream 
effectors which mediate insulin action include translocation of the glucose transporter (GLUT1 
or 4) to the plasma membrane (Shulman et al., 2000) and PKB/Akt mediated inhibition of 
GSK-3 (Cheng et al., 2010). 
The growth and mitogenic actions of insulin involve the MAPK-dependent pathway, which is 
initiated by activation of Shc, Grb-2, Ras and Sos (Carel et al., 1996). Following Ras activation, 
Raf is recruited to the cell membrane which stimulates a signalling cascade by phosphorylation 
of MAPK which in turn phosphorylates and activates downstream proteins such as extracellular 
regulated kinase (ERK1/2) (Sasaoka et al., 1994). 
Contrary to normal insulin signaling, conditions of insulin resistance lead to inhibition 
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of the metabolic pathway (PI3K) and overstimulation of the growth-factor like pathway 
(MAPK), resulting in  a decrease in glucose uptake and possibly affecting  normal metabolic 
function (Van Gaal et al, 2006). 
 
 
Figure 1.1 Insulin signaling pathway. Binding of insulin to the insulin receptor initiates a 
signaling cascade that involves multiple phosphorylation events (green circles) and leads 
to alterations in glucose and lipid metabolism (Turner, 2013). 
IRS, insulin receptor substrate; SHC, Src Homology 2 domain; GRB2, growth factor receptor-
bound protein 2; ERK, extracellular- signal-regulated kinases or classical MAP kinases; PI3K 
Phosphoinositide 3-kinase; PDK1, phosphoinositidedependent protein kinase 1; mTORC 
mammalian target of rapamycin complex; FoxO1 Forkhead box protein O1; SREBP1c sterol 
regulatory element binding protein 1c; GSK-3, glycogen synthase kinase 3; AS160, 160 kDa 
Akt substrate. 
 
 
The molecular mechanisms of insulin resistance in type 2 diabetes have not been fully 
characterized, although many important biochemical, metabolic, and genetic features have 
been identified. Accumulated findings have highlighted several pathways in insulin resistance, 
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including lipid accumulation, oxidative stress, and inflammation (For a review see Bunner et 
al., 2014).  
An important common feature of these mechanisms is the activation of stress-sensitive kinases 
including protein kinase C ζ (PKCζ). PKCζ depends on lipids for activation (such as 
diacylglycerol/DAG and fatty acyl-CoA). When activated, PKCζ has the ability to enhance the 
inhibition of nuclear factor kappa-B (IKK-β) while both c-Jun N-terminal kinase 1 (JNK1) and 
PKCζ will phosphorylate IRS-1 on serine residues, thereby hindering tyrosine phosphorylation. 
Diminished tyrosine phosphorylation of IRS-1 reduces signaling through the PI3-kinase/Akt 
pathway interfering with binding of IRS1/2 to the insulin receptor, ultimately affecting insulin 
signalling (Schmitz-Peiffer & Biden, 2008; Morino et al., 2006). 
 
Figure 1.2 Insulin actions in insulin-sensitive tissues (Bunner A et al., 2014).  
The different actions of insulin in insulin-sensitive tissues. In muscle, insulin increases glucose 
uptake and glycogen synthesis. In liver, it promotes glycogen synthesis and lipogenesis and 
decreases gluconeogenesis and the release of stored glucose. In adipose tissue, it increases 
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glucose uptake and lipogenesis and decreases lipolysis. In the brain, insulin inhibits hepatic 
glycogenolysis and lipolysis and decreases appetite.  
 
1.5.3 The role of adipose tissue-derived hormones (adipokines) in insulin resistance 
 
Several possible mechanisms linking insulin resistance to obesity have been postulated. 
Qatanani and Lazar (2007) very elegantly stated that the link between obesity and insulin 
resistance is possibly a ‘cause and effect’ relationship as changes in body weight   (loss/gain) 
are closely correlated to insulin sensitivity/resistance, respectively. 
Many of the adipose tissue secretions have been found to contribute to insulin resistance, 
metabolic disturbances and cardiovascular risk (Van Gaal et al., 2006). 
 
1.5.3.1 TNFα 
It is well known that in obesity, circulating levels of TNFα are elevated which may be attributed 
to macrophage infiltration in the expanded adipose tissue (Qatanani & Lazar, 2007). TNFα 
increases the release of FFA (Sethi & Hotamisligil, 1999), which in turn leads to increased 
accumulation of triglycerides, LDL-c and VLDL-c, while HDL-c levels are decreased. TNFα 
can also directly interfere with insulin signaling in adipocytes by down-regulating several steps 
in the insulin signalling cascade. It achieves this by increasing serine phosphorylation of insulin 
receptor substrate-1 (IRS-1), inhibiting insulin receptor tyrosine kinase activity, thus blocking 
the downstream events of insulin signalling, including the insulin-sensitive expression of the 
glucose transporter GLUT4 as well as the translocation of GLUT4 to the plasma membrane, 
eventually reducing insulin-induced glucose uptake. TNFα also stimulates the expression of 
leptin, plasminogen activator inhibitor-1 (PAI-1) and IL-6 (For review see Bakhai, 2008; 
Grattagliano et al., 2008). 
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1.5.3.2 Leptin and insulin resistance 
 
The physiological role of leptin in both obese and lean subjects has received much attention 
(For reviews see Yingzhong et al., 2006; Jung & Choi, 2014). Initial studies performed on 
leptin demonstrated that it controls body weight and appetite via the hypothalamus. 
Interestingly, inflammation induced by metabolic stress negatively regulates leptin signaling 
in a manner similar to insulin receptor signalling as both of these signalling pathways in the 
hypothalamus are integrated through the PI3K pathway, among others. Also, loss of leptin 
and/or insulin signalling in the hypothalamus can promote obesity and type 2 diabetes (Morton 
et al., 2005; Zhang et al., 2008; for a review see Cao, 2014).  Leptin signalling includes the 
JNK and the activators of transcription (JAK-STAT) pathways (Yingzhong et al., 2006; Xu et 
al. 2013).  
Recent evidence now indicates that the brain processes information from adiposity signals such 
as insulin and leptin, which circulate in proportion to body fat mass, and integrates this input 
with signals from nutrients such as fatty acids (Qatanani & Lazar, 2007). Apart from the action 
of leptin to modify metabolism via the brain, leptin may have important effects through direct 
action on peripheral target cells, including β cells, liver, muscle, and fat (Kahn and Flier, 2000). 
In addition, hyperinsulinemia and insulin resistance are associated with elevated serum leptin 
levels (Kim-Motoyama et al., 1997) through dysregulation of the adipose tissue-hypothalamic 
axis (Almanza-Perez et al., 2008).  Morrison et al. (2009) reported that leptin can either 
modulate insulin sensitivity or be induced by insulin.  
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1.5.3.3 Adiponectin and insulin resistance 
 
Expression of adiponectin in adipose tissue is lower in subjects with obesity and insulin 
resistance than in lean subjects where it is associated with higher degrees of insulin sensitivity 
and lower adipose TNF-α expression (For a review see Jung & Choi, 2014).  
Researchers employing rhesus monkeys to study obesity and type 2 diabetes found reduced 
adiponectin levels in the advancement of insulin resistance and type 2 diabetes  (Hotta et al., 
2001). In addition, several groups have reported that obese mice lacking adiponectin develop 
insulin resistance as a result of TNFα overproduction in adipose tissue causing defects in  
insulin signalling and reduced responsiveness to PPARγ (Maeda et al., 2001; For a review see 
Cao, 2014).  
 
The adiponectin receptors (AdipoR1 and AdipoR2) are important in adiponectin signaling and 
are vital components of metabolic processes mediating increased AMP kinase (AMPK) 
activity, fatty acid oxidation (in peripheral tissue) (Tomas et al., 2002) glucose uptake and 
PPARγ ligand activity in the liver thereby promoting insulin sensitivity (Kadowaki et al., 2007; 
Pajvani et al., 2003).  
 
 
1.5.4 Insulin resistance and oxidative stress 
 
Oxidative stress 
It has now been firmly established that obesity is associated with chronic, low-grade 
inflammation due to changes in function of adipocytes and macrophages (for a review see Hajer 
et al. 2008) and oxidative stress.  
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Under normal conditions, tissue oxidant and antioxidant activity is balanced. This is achieved 
by antioxidants, including enzymes such as cytosolic or mitochondrial superoxide dismutase 
(SOD), glutathione peroxidase (GPx) and catalase as well as non-enzymatic compounds such 
as vitamins E and C. However, a ‘pro-oxidative’ condition arises when the balance between 
oxidants and antioxidants is disturbed, resulting in oxidative tissue damage or oxidative stress 
(Bondia-Pons et al., 2012). 
Thus, oxidative stress is defined as an impaired balance between production of reactive oxygen 
species (ROS) and/ or reactive nitrogen species (RNS) and an insufficient antioxidant capacity 
to overcome the production (Eriksson, 2007), resulting in accumulation of oxidative products. 
Major ROS variants include hydrogen peroxide (H2O2), hyperchlorous acid (HOCL), 
superoxide (•O2¯ ), hydroxyl (•OH), peroxyl (•RO2¯ ) and hydroperoxyl (•HO2¯ ) radicals 
while RNS consist of nitric oxide (NO) and peroxynitrite anions (ONOO¯ ) (Evans et al., 2005). 
It is well-known that oxidative stress plays an important role in many pathological conditions 
and human disease states, as well as with the onset, and all components of cardiovascular 
complications (For a review see Wellen & Hotamisligil, 2005; Furukawa et al., 2004). 
Malondiadehyde (MDA), lipid hydroperoxides and thiobarbituric reactive acid substrates 
(TBARS) are established markers for determining the levels of lipid peroxidation in tissue 
damaged by oxidative stress (Siddiqui et al. 2014; Van Gaal et al., 2006). 
 
 
1.5.4.1 Oxidative stress and insulin resistance 
 
Oxidative stress as a causal factor in the development of insulin resistance has been supported 
by several studies and many findings suggest that the reversal of oxidative stress by the use of 
antioxidants may improve insulin resistance (Qatanani & Lazar, 2007). 
Stellenbosch University  https://scholar.sun.ac.za
18 
 
Since oxidative stress is considered to be the common factor underlying insulin resistance, type 
2 diabetes and cardiovascular disease, it may explain the presence of inflammation in all of 
these conditions (Van Gaal, 2006). In response to converting excessive amounts of FFA and 
other nutrients into fat, adipocytes can develop signs of oxidative and endoplasmic reticulum 
(ER) stress (Van Gaal, 2006; Boden, 2011). 
 
A decrease in mitochondrial function associated with obesity and insulin resistance has been 
highlighted by Evans and coworkers (2002). Although paradoxical, the increases in ROS 
production induced by FFA, requires functional mitochondria, suggesting that FFA oxidation 
may occur before mitochondrial dysfunction and establishment of insulin resistance (Petersen 
& Schulman, 2006)  
The peroxisome proliferator-activated receptor coactivator 1 (PGC-1α) is highly expressed in 
tissue containing numerous mitochondria such as brown adipose tissue (BAT) and skeletal 
muscle, with lower expression in white adipose tissue (WAT) and the liver (Puigserver et al., 
1998). 
PGC-1α, an important regulator of mitochondrial biogenesis, is activated by increased nutrient 
supply as seen in obesity (Lin et al., 2005) and has been associated with improved 
mitochondrial function as well as increased insulin sensitivity, which supports the idea that 
insulin resistance might arise from defects in mitochondrial function. This in turn leads to 
increases in FFA metabolites, such as fatty acyl-CoA and DAG that disrupt insulin signaling 
in muscle and liver (Qatanani & Lazar, 2007).  
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1.6 The metabolic syndrome (MetS) 
 
The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors including 
hypertension, hyperglycemia, hypertriglyceridemia, decreased high-density lipoprotein-
cholesterol, and central obesity. MetS was reported to be associated with increased risks of 
type 2 diabetes mellitus, cardiovascular and cerebrovascular events, and chronic kidney disease 
(Isomaa et al., 2001; Meigs et al., 2007). 
The pathophysiological mechanisms through which overweight/obesity progress to the 
metabolic syndrome, remain unclear. However, it is known that obesity-induced inflammation 
plays an important role in the development of insulin resistance that triggers the associated 
comorbidities of metabolic syndrome, as mentioned above. In addition to an increased risk for 
type 2 diabetes and cardiovascular disease, the comorbidities of MetS also include, obstructive 
sleep apnoea syndrome, fatty liver disease as well as sleep/wake disturbances (Wilcox et al., 
1998; For a reviews see Bakhai, 2008 and Nduhirabandi et al., 2012). 
Obesity is associated with a clustering of atherogenic risk factors, and when three or more are 
present, it generally signifies insulin resistance or metabolic syndrome (Reavan, 2004). This is 
promoted by weight gain and visceral adiposity (Veronica & Esther, 2012). The metabolic 
syndrome is further characterized by high levels of fasting glucose and triglycerides, low levels 
of high-density lipoprotein (HDL) and hypertension (Slanovic-Kuzmanovic et al., 2013).  
  
Accumulating evidence suggest that visceral obesity is a central component of this syndrome 
and insulin resistance a triggering factor, as well as genetics, ethnicity, hormonal changes and 
ageing, which may also be involved in the development of this syndrome. However, the precise 
underlying cause is yet to be established (Hausman et al., 2001). 
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 Matsuzawa et al. (2004) performed clinical studies on obese individuals to investigate the 
associated morbidities and showed that the distribution of body fat, rather than the extent of fat 
accumulation, is the more important determinant of the morbidity of obesity-related disorders. 
The accumulation of visceral adipose tissue is therefore an important factor in the developing 
of diabetes mellitus, hypertension, hyperlipidemia, atherosclerosis, or their coexistence, as seen 
in the metabolic syndrome (Hausman et al., 2001). 
In addition to adiposity, a subtle interplay for adipokines in the development of MetS has been 
suggested (for a review see Cao, 2014). This occurs by dysregulation of adipose tissue 
(adipocytes) caused by visceral fat accumulation leading to oversecretion of leptin and TNFα 
and diminished secretion of adiponectin, resulting in metabolic disorders, specifically 
dyslipidemia, characterized by small dense low-density lipoprotein (LDL) (Grattagliano et al., 
2008). 
 
A potential role for oxidative stress is increasingly being recognized as a common factor in 
MetS (Furukawa et al., 2004) as well as its involvement in the pathogenesis of vascular 
alterations such as atherosclerosis (Palmieri et al., 2006), obesity and diabetes associated with 
the metabolic syndrome (Grattagliano et al., 2008). 
 
 
1.7 MYOCARDIAL ISCHAEMIA-REPERFUSION: AN OVERVIEW 
 
Ischaemia refers to an imbalance between the demand for and supply of coronary blood to 
tissue, causing an inadequate supply of oxygen and nutrients to maintain cellular metabolism 
(Hearse, 1977). 
Myocardial ischaemia or ischemic heart disease (IHD) is the leading cause of death worldwide 
(Hausenloy & Yellon, 2008). Several risk factors are involved in the development thereof 
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(Ferdinandy et al., 2007) and even though this condition has mixed environmental and genetic 
etiologies, it occurs mainly in the context of severe and prolonged myocardial ischemic events 
or in clinical situations where untreated atherosclerotic plaques in coronary arteries, can 
progress to myocardial infarction (MI) or cell death. (Garcia-Dorado et al., 2014; Opie, 2004) 
The changes in the myocardium induced by ischaemia following acute coronary occlusion (20 
or more minutes) include: a block in oxidative metabolism, mitochondrial swelling, rapid ATP 
depletion (Braasch et al, 1968), lactate accumulation, tissue acidosis (Lemasters et al, 1996) 
associated with changes in intracellular sodium and calcium ions (Turer & Hill, 2010).The 
subsequent loss of structural integrity is believed to be due to sarcolemma (SL) disruption as 
well as swelling of mitochondria (for a review see Jennings, 2013). In addition, the damage 
caused by myocardial ischaemia can be classified into reversible and irreversible, depending 
on the severity and length of the reduction in coronary flow as well as the location of the 
ischemic insult (Skyschally et al., 2008).  
Early reperfusion is essential for maintaining cell viability and protecting the heart against 
infarction. The process of restoring coronary blood flow is associated with the washout of 
ischaemic metabolites along with the re-admission of oxygen and metabolic substrates, causing 
changes in structure, function and biochemistry (Edoute et al., 1983), and may ultimately 
determine the fate of the cell (survival or death). Paradoxically, myocardial reperfusion per se 
can also induce injury and cell death thereby reducing its beneficial effects (Frolich et al., 
2013), the so-called phenomenon of ischaemia/reperfusion injury. The following section will 
briefly highlight the myocardial alterations and damage incurred by ischaemia/reperfusion. 
1.7.1 ISCHAEMIA-REPERFUSION INJURY 
The concept of ischaemia/reperfusion (I/R) injury usually refers to a combination of the injury 
induced by sustained ischaemia and reperfusion. Experimentally it is difficult to discern 
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whether a damaged piece of myocardium was injured by ischaemia or reperfusion, or a blend 
of both (Skyschally et al., 2008). 
At the onset of ischaemia, rapid ultrastructural changes occur in the myocardium (Edoute 1983, 
Ferdinandy et al., 2007). The duration of the ischemic episode and the application of 
reperfusion will determine whether the injury to the myocardium is reversible or irreversible 
(Yellon & Hausenloy, 2007). Three types of myocardial injury have been identified i.e. 
arrhythmias, myocardial stunning and irreversible/lethal reperfusion injury. 
 
Arrhythmias occur as a result of electrical changes in ion channels or disrupted ion homeostasis 
and are usually associated with a short period of ischaemia (±5 minutes) and a reduction in 
blood flow and contractility, but can be reversed by reperfusion (Roden et al., 2002).  
Myocardial stunning (or ‘mechanical dysfunction’) refers to a transient period of depression in 
myocardial function occurring during reperfusion after a usually longer period of ischaemia 
and represents a non-lethal form of reperfusion injury (Yellon & Hausenloy, 2007; Frolich et 
al., 2013; Kloner et al., 1989). Although there is still some controversy regarding the exact 
causal factors, oxidative stress (as occurs during early reperfusion) and intracellular calcium 
overload are important role players in this phenomenon (Bolli & Marban, 1999). 
 The third type of injury is associated with ischaemic periods lasting longer than 20 minutes, 
resulting in myocardial infarction (Skyschally et al. 2008; Opie et al. 2004). In a study using a 
canine heart model, Jennings (1957) demonstrated that increased amounts of necrosis became 
evident after a prolonged ischemic episode of 60 minutes. Failure to recover upon reperfusion, 
indicated irreversible injury. Histological features of the irreversibly damaged canine 
myocardium included cardiomyocyte swelling, contraction bands (myofibrils), disrupted 
sarcolemma and the presence of intramitochondrial calcium phosphate granules (for a review 
see Jennings, 2013). 
Stellenbosch University  https://scholar.sun.ac.za
23 
 
Irreversible injury can further be defined as death/loss of cardiomyocytes (through apoptosis 
and necrosis) which were viable during ischaemia and irreversibly damaged upon reperfusion 
(Kloner et al., 1989; Skyschally et al., 2008).  
In view of this, several studies focused on the ability of interventions induced at the beginning 
of reperfusion to reduce myocardial infarct size. Reductions in myocardial infarct size of 40-
50% have been reported, making it an important target for cardioprotection (For reviews see 
Yellon & Hausenloy, 2007; Frolich et al., 2013). 
 
 
1.7.2 Pathophysiology of ischaemia-reperfusion injury 
 
Restoration of myocardial blood flow to reversibly injured myocytes leads to recovery of 
mitochondrial respiration, ATP synthesis, normalization of hydrogen, sodium and calcium 
concentrations, marked ultrastructural improvement and generation of creatine phosphate, 
despite the presence of ischaemia-reperfusion injury (Edoute et al., 1983). The deleterious 
effects of reperfusion during the first few minutes include macrophage activation, ROS 
overproduction and oxidative stress (Tapuria et al., 2008).  
After prolonged ischaemia, reperfusion can no longer reverse the continued damage causing 
intracellular calcium overload and ATP depletion resulting in the eventual opening of 
mitochondrial permeability transition pore (MPTP) and cell death (Dominguez-Rodriguez et 
al., 2014).  
Other factors implicated in reperfusion injury include, extracellular and intracellular edema 
contributing to changes in the mechanical function of the myocardium, platelet accumulation, 
(Garcia-Dorado et al., 2014), renin-angiotensin system (RAAS) (angiotensin-II increases 
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calcium and induces necrosis) and complement system activation (directly induces cell injury 
by increasing cell permeability and releasing histamine) (Dominguez-Rodriguez et al., 2014). 
Innovative treatment strategies aimed at protecting the myocardium against the detrimental 
effects of ischaemia/reperfusion injury are needed to improve the prognosis of CHD patients. 
In order to do so, knowledge of events occurring at an intracellular level is a prerequisite. 
 
 
1.7.3 The mitochondrial permeability transition pore (MPTP) 
 
In the heart, mitochondria serve to provide ATP for contraction and maintenance of ionic 
homeostasis. The inner membrane of mitochondria (in mammals) contains a mitochondrial 
permeability transition pore (MPTP) (for a review see Halestrap & Richardson, 2014), which 
allows communication between the cytoplasm and mitochondrial matrix (Hunter et al., 1976). 
Opening of the MPTP during reperfusion injury has indeed been associated with increased Ca2+ 
levels, apoptosis, cytochrome c (Cyt C) release and elevated ROS levels (Littlejohns et al., 
2014; for reviews see Perrelli et al., 2011; Halestrap & Richardson, 2014).  
Furthermore, MPTP opening is also involved in determining the extent of injury to the 
myocardium during reperfusion, after a prolonged ischaemic episode (Hausenloy et al., 2009; 
for a review see Halestrap & Richardson, 2014).  
Interestingly, in a study using a rabbit model, MPTP inhibitors (cinnamic anilides) were shown 
to be cardioprotective against acute myocardial infarction (AMI), (Fancelli et al., 2014) which, 
along with other established cardioprotective regimes, mediate their effects via inhibition of 
MPTP opening (for a review see Halestrap & Richardson et al., 2014). Other inhibitors of 
MPTP opening include cyclosporine A (CsA) (Hausenloy et al., 2003) and melatonin 
(Petrosillo et al., 2009).  
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1.7.4 Concepts of cell death: Necrosis, Apoptosis and Autophagy 
According to Tian et al. (2013), cell death (progressive or acute) denotes an irreparable damage 
of plasma membrane integrity and can be classified into necrosis, apoptosis and autophagy, 
each with different morphological manifestations.  
Cell death is a physiological process that serves to regulate tissue homeostasis and is considered 
as a ‘hallmark characteristic’ of cardiovascular diseases, including acute myocardial infarction 
(Whelan et al., 2010). 
Apoptosis is a tightly regulated, energy-dependent process that occurs under both physiological 
and pathological conditions. It is responsible for normal cell turnover and immune system 
function in addition to its ability to act as a defence mechanism when cells are damaged 
(Elmore et al., 2007). It consists of two pathways namely, the death receptor pathway 
(stimulated by TNF-α) and the mitochondrial pathway which is activated under conditions of 
ischaemia with increased Ca2+, ROS and acidosis, playing a significant role in myocardial 
infarction (Kim &  Kang, 2010). 
Necrosis or ‘uncontrolled cell-death’ refers to the changes that occur in cells and tissue after 
the cells have died (Kanduc et al., 2002). Unlike apoptosis, necrosis is associated with energy 
depletion, swelling, inflammation and disruption of sarcolemma and mitochondria. With 
regard to the myocardium, it has been reported to occur after prolonged ischaemia and is 
associated with irreversible injury (for a review see Jennings, 2013). 
Lastly, autophagy is a cell survival mechanism involving degradation and recycling of 
cytoplasmic components and restoration of homeostasis (for reviews see Booth et al., 2014; 
Tian et al., 2013). However, if stresses persist and autophagy can no longer support cell 
survival, cells respond to apoptosis for elimination. This process also occurs without 
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inflammation, suggesting a cross-talk between apoptosis and autophagy (for a review see Booth 
et al., 2014). 
In addition, autophagy is regulated by several signalling pathways including nutrient, 
insulin/growth factor and energy sensing pathways and is also involved in ischemic heart 
disease and heart failure (Tian et al., 2013). 
 
 
1.7.5 Protection of the ischemic heart: ischemic preconditioning (IPC) and postischemic 
conditioning (IPOC) 
 
The heart has a powerful endogenous protective mechanism at its disposal against 
ischaemia/reperfusion damage. Several forms have been identified namely ischemic 
preconditioning (IPC), remote preconditioning and ischemic postconditioning (IPOC) (for a 
review see Bousselmi et al., 2013). A detailed description of these phenomena falls beyond the 
scope of this thesis.  
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Figure 1.3 Mapping preconditioning's signaling pathways (Downey et al., 2008). 
During ischaemic preconditioning, adenosine, opioids, and bradykinin are released from the 
heart. Opioid and bradykinin receptors causes activation of Akt via phosphatidylinositol 3-
kinase (PI3-kinase) activation. PI3-kinase causes extracellular signal regulated kinase (ERK)-
dependent activation of endothelial nitric oxide synthase (eNOS), which activates guanylyl 
cyclase resulting in cyclic GMP-dependent protein kinase (PKG) activation through production 
of cyclic guanosine monophosphate (cGMP). This activation causes the opening of ATP-
sensitive potassium channels on the inner membrane of the mitochondria, resulting in 
generation of free radicals during reperfusion when oxygen is reintroduced. These radicals then 
activate protein kinase C (PKC) and put the heart into the protected phenotype that persists for 
one to two hours. Although adenosine receptors activate PI3-kinase, they also have a second 
direct coupling to PKC and thus bypass the mitochondrial pathway. 
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1.7.6 Cardioprotection associated with the RISK and SAFE pathways 
 
Early coronary artery reperfusion is still known as the most effective means of controlling 
infarct size (Hausenloy & Yellon, 2007). Interventions such as IPC and several 
pharmacological agents (opiods, bradykinins, growth factors, etc.) have been associated with 
the activation of important cardioprotective pathways during early reperfusion. The 
Reperfusion Injury Salvage Kinase (RISK) pathway which includes the pro-survival kinases, 
PKB/Akt and ERK1/2, which when activated at the time of reperfusion, is associated with 
powerful protection by preventing lethal reperfusion injury (Fig 1.2). It can also be perceived 
as a mediator of ‘programmed cell survival’ involving inhibition of MPTP opening, 
normalizing Ca2+ levels as well as recruitment of antiapoptotic pathways (for a review see 
Yellon & Hausenloy, 2007). 
 
Protection can also be conferred by The Survivor Activating Factor Enhancement (SAFE) 
pathway consisting of signal activator and transducer 3 (STAT-3) and tumor necrosis factor-α 
(TNF-α). Activation of the SAFE pathway, induced by low doses of TNF-α, has been shown 
to protect against experimental lethal reperfusion injury (Lecour, 2009). 
In addition, inhibition of the mitochondrial permeability transition pore (MPTP) and ATP-
dependent mitochondrial potassium channel (mKATP) as well as protein kinase C have all 
shown to be involved in cardioprotection (for reviews see Hausenloy & Yellon, 2008 and 
Yellon & Hausenloy, 2007).  
 
1.7.7 Effects of obesity on myocardial ischaemia/reperfusion injury  
As stated in the introduction of this chapter, obesity is considered to be a serious risk factor in 
the development of cardiovascular disorders and is traditionally regarded to impact negatively 
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on the outcome of myocardial ischaemia. However, despite the evidence for a higher 
prevalence of obesity in myocardial ischaemia patients, a number of recent publications 
suggested that obesity in humans with ischaemic heart disease is associated with reduced 
morbidity and mortality, the so-called “obesity paradox” (Chase et al., 2014; Clark et al., 2014; 
Diercks et al., 2006). The mechanism underlying this paradox is complex and remains unclear.  
 
To elucidate the pathophysiological mechanisms underlying the relationship between obesity 
and cardiovascular disease (CVD), extensive use has been made of experimental animals fed 
high calorie or high fat diets. Unfortunately experimental data on the impact of diabetes, 
obesity and insulin resistance on myocardial ischaemia/ reperfusion injury (IRI) are very 
controversial (for reviews see references Miki et al., 2012; Whittington et al., 2012). In contrast 
to the vast amount of research done to assess the susceptibility of the heart to 
ischaemia/reperfusion damage in types I and II diabetes (Miki et al., 2012; Whittington et al., 
2012; Balakumar et al., 2009), not much is known about the effects of obesity per se in this 
regard. Experimental studies have reported a decreased myocardial tolerance to ischaemia-
reperfusion damage in in vivo (Clark et al., 2011; Wensley et al., 2013) and ex vivo (Du Toit et 
al., 2008; Nduhirabandi et al., 2011) studies using hyperphagia-induced obese insulin resistant 
male rats as well as in other animal models (Sidell et al., 2002; Thakker et al., 2008; Bouhidel 
et al., 2008). Together, these studies have demonstrated an association between increased 
infarct size and poor functional recovery in hearts from obese animals compared to the controls. 
However, in a hyperphagia-induced obese rat model, Donner and coworkers have reported 
smaller infarcts and improved functional recovery during reperfusion (Donner et al., 2013). 
Similar beneficial effects of obesity have been observed in our own laboratory (Salie et al., 
2014), suggesting that the variation in susceptibility to ischaemia/reperfusion damage may be 
due to differences in the age of the animals and the duration of obesity.  
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It is now generally accepted that activation of the reperfusion injury salvage kinase pathway 
(RISK) is characteristic of a reduction in injury during reperfusion (Hausenloy et al., 2005, 
Hausenly & Yellon, 2007), which is further associated with activation of the prosurvival/anti-
apoptotic kinase PKB/Akt, a key enzyme in the insulin signalling pathway (Huisamen, 2003). 
However, conclusions about the RISK pathway’s involvement in models of obesity and insulin 
resistance are hampered  by the facts that not only do the models of diabetes differ, but tissue 
samples are taken at different times during the experimental protocol. For example, samples 
were collected at the end of the stabilization time (Tsang et al., 2004), during reperfusion after 
sustained ischaemia (Xu et al., 2004) or under baseline conditions (Donner et al., 2013; 
Strniskova et al., 2003). Baseline activation of ERK was found to be increased in 
streptozotocin-induced diabetes (Strniskova et al., 2003) while both ERKp44/p42 and 
PKB/Akt phosphorylation were reported to be lower in rats on a high fat diet (Wensley et 
al.,2013). ERK activation during reperfusion of streptozotocin-induced diabetic hearts is 
dependent on the duration of hyperglycaemia: an increment is seen after 4 weeks followed by 
a significant reduction after 20 weeks (Xu et al., 2004), while PKB/Akt activation showed a 
similar early stimulation followed by a reduction (Ma et al., 2006). Clearly more experimental 
work is required to elucidate these discrepancies. 
 
 
1.8 EFFECTS OF MELATONIN ON OBESITY AND THE HEART 
 
An overview 
Several physiological processes are influenced by the 12 hour day/night circadian cycle.  
An important function of this cycle is the adjustment of the master circadian clock, the 
hypothalamus, including sleep/activity regulation and appetite control (for reviews see Froy 
2010, 2011; Lima et al., 2013). 
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Melatonin (N-acetyl-5-methoxytryptamine) is an evolutionary conserved, pineal gland 
hormone that is found in animals, humans (Reiter, 1999; Hardeland & Poeggeler, 2012) and 
plants (Reiter et al., 2007).  
Melatonin is undoubtedly under the control of the master circadian clock and is synthesized 
and released in a rhythmic fashion such that its production is circumscribed to the night (Reiter, 
1991) with circulating levels of 43-400pM at night and 10-60pM during the day (Barrenetxe et 
al., 2004).  
 
Melatonin was initially identified by Lerner  and coworkers  (1958) and subsequently 
demonstrated in a variety of organisms, from protozoa, bacteria, invertebrates to vertebrates 
(Hardeland & Fuhrberg, 1996). Its biosynthesis has been described by Pandi-Perumal et al. 
(2006), Reiter et al. (2007), Tan et al. (2002) and Zawilska et al. (2009) and involves two key 
enzymes: serotonin (arylalkylamine)-N-acetyltransferase (AA-NAT) and hydroxyindole-O-
methyl transferase (HIOMT) ,which are responsible for the conversion of serotonin to 
melatonin. 
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Figure 1.4 Melatonin biosynthesis and metabolism (Karasek & Winczyk, 2006). 
The synthetic pathway and metabolism of melatonin from tryptophan to 6-hydroxymelatonin 
sulphate and 6-hydroxymelatonin glucuronide. 
 
Due to its amphiphilic nature, melatonin can enter body fluids as well as all cellular and sub-
cellular compartments (Vural et al., 2001), displaying a wide range of physiological functions 
such as regulation of circadian rhythms acting as a chronobiotic or ‘internal synchronizer’. It 
possesses powerful antioxidant, anti-inflammatory (for review see Tengattini 2008; Hardeland 
et al., 2006), anti-adrenergic actions (Lochner et al., 2013), as well as body weight and energy 
metabolism regulation (Korkmaz et al., 2009). 
In view of this, several studies have sought to investigate melatonin’s actions at a 
cellular/molecular level to better understand its pleiotropic effects (Luchetti et al., 2010) which 
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occur mainly through the activation of membrane or nuclear receptors in various tissues, 
allowing them to respond to the circadian melatonin message (Reiter et al., 2008). 
 
 
1.8.1 Melatonin signaling: role of melatonin receptors 
 
Melatonin possess all characteristics of a classical hormone, being centrally produced in an 
endocrine gland, having the ability to circulate in a free and albumin-linked form, and acting 
through specific G-protein-coupled membrane receptors namely, MT1 and MT2 (for a review 
see Cipolla-Neto et al., 2014). These receptors have been identified in several organs including 
the liver, lungs, heart and the central nervous system (CNS) (Naji et al., 2004), however, its 
signaling in the heart has not been studied in sufficient detail. 
It is well established that coupling of melatonin to its receptors (MT1 and MT2) can activate 
various signal transduction cascades, eliciting a number of cellular responses (Pandi-Perumal 
et al., 2008), including the regulation of antioxidant enzymes (Rodriguez et al., 2004).  
 
Melatonin’s intracellular signaling is mediated by the G inhibitory protein, which upon binding 
of melatonin to its receptors (MT1 and MT2), leads to increases in cytosolic Ca2+ due to 
stimulation of phospholipase C  and  phosphorylation of protein kinase C (PKC) (for a review 
see Luchetti et al., 2010), ultimately leading to activation of CREB (cAMP responsive element 
binding protein) and the regulation of antioxidant enzymes, accounting for the indirect 
antioxidant actions of melatonin (Tengattini et al., 2008; for a review see Luchetti et al., 2010).  
On the other hand, the direct free radical scavenging actions of melatonin account for its 
receptor-independent actions (Cipolla-Neto et al., 2014; Nduhiranadi et al., 2012).  
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1.8.2 Melatonin, a powerful antioxidant  
 
The antioxidant properties of melatonin have been widely reviewed in view of the fact that 
several pathophysiological conditions are associated with increased oxidative stress (e.g. 
cardiovascular disease, type 2 diabetes, Alzheimer’s disease, amongst many others) (Allegra 
et al., 2003; Reiter et al., 2009; Lochner et al., 2013; ). 
 
The discovery of the high efficacy of melatonin as a free radical scavenger in 1993 (Tan et al., 
1993) stimulated several studies. It was found that melatonin does not require the formation of 
a complex with a receptor or molecule to be able to act as a free radical scavenger.  Thus its 
receptor-independent actions only require that melatonin be in the vicinity of ROS/RNS when 
it is generated, for scavenging of the free radicals (Reiter et al., 2008) 
Melatonin has been documented as a potent scavenger of the hydroxyl radical (·OH) since 
excess ·OH generation due to ionizing radiation was found to be reduced in its presence (Zhou 
et al., 2006; for a review see Reiter et al., 2008). Moreover, the molecule that is formed when 
melatonin scavenges two ·OH radicals or when it interacts with the peroxynitrite anion 
(ONOO-), 3-hydroxymelatonin (3-OHMEL), also possesses potent free radical scavenging 
properties and in doing so, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) is formed 
(Tan et al., 2000). In turn when AFMK encounters ROS/RNS, this leads to the formation of 
N1-acetyl-5-methoxykynuramine (AMK), and its interaction with (ONOO-) also produces 
ROS/RNS scavengers. Other free radicals that melatonin can scavenge include, hydrogen 
peroxide, superoxide and nitric oxide, amongst others.  
 
It was also shown that melatonin can reduce mitochondrial free radical formation, and inhibit 
the opening of the mitochondrial permeability transition pore (MPTP), suggesting a 
cardioprotective role of melatonin (Petrosillo et al., 2009). It has further been determined that 
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a single melatonin molecule (via AFMK) has the ability to scavenge up to 10 free radical 
species (ROS/RNS) (Tan et al., 2007). 
 
This process whereby melatonin along with its metabolites neutralizes toxic reactants is known 
as the antioxidative cascade (for reviews see Hardeland, 2005; Tan et al., 2007; Reiter et al., 
2008). Importantly, studies employing melatonin (up to 1 g daily), far above its physiological 
range, showed no toxicity (Bonnefont-Rousselot & Colin, 2010; Tan et al., 2011). 
 
It is also known that melatonin has the ability to stimulate antioxidant enzymes, such as 
glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase (CAT), glutathione 
reductase (GRd) and glucose-6-phosphate dehydrogenase (G6PD) (for reviews see Reiter et 
al., 2000, 2008). In addition, exogenous melatonin treatment reduces the activity of the pro-
oxidant enzymes (nitric oxide synthases, myeloperoxidases) and downstream inflammatory 
cascades (Hardeland, 2005; Galijsevic et al., 2008). Positive correlations with the level of 
antioxidants and serum melatonin have also been made, suggesting a role for melatonin as a 
modulator of oxidative stress via these antioxidant actions (Bonnefont-Rousselot & Collin, 
2010). 
 
 
1.8.3 Melatonin, metabolic regulation and obesity 
 
1.8.3.1 Body weight regulation  
 
The ability to balance energy intake, storage and expenditure is a prerequisite of life and 
ultimately determines the final body weight. The state of being overweight or obese results 
from an inbalance between energy intake and expenditure. 
Stellenbosch University  https://scholar.sun.ac.za
36 
 
The circadian clock is known to govern all peripheral clocks and as a result, behavioural and/or 
physiological changes in many species (Panda et al., 2002; Reppert & Weaver, 2002). It is 
reportedly known to regulate metabolism and energy homeostasis in several organs, including 
the liver and peripheral tissue. Growing evidence suggests that metabolism, energy intake and 
timed meals are linked to circadian rhythms. Furthermore, metabolic disorders have been 
associated with disruption of circadian rhythms (for a review see Froy, 2010). 
Melatonin is well-known for its chronobiotic effects and circadian entrainment (Reiter et al., 
2012).  Bartness & Wade (1985) reported on its role in body weight regulation by 
demonstration of body weight gain in pinealectomized rats with low circulating melatonin 
levels. On the other hand, intraperitoneal (ip) melatonin supplementation of 30mg/kg/day for 
3 weeks to pinealectomized rats, reversed the body weight gain (Prunet-Marcassus et al., 2003). 
 
The role of melatonin in body weight regulation is further underscored by the demonstration 
that, in a rat model of diet-induced obesity, a daily melatonin supplementation was shown to 
significantly reduce plasma glucose, leptin, triglyceride (TG) as well as total cholesterol levels, 
along with reductions in body weight gain, independent of food consumption (Rasmussen et 
al., 1999; Wolden-Hanson et al., 2000; for a review see Nduhirabandi et al., 2012).  
In a 12 week high-fat diet study carried out by Hussein et al. (2007), the diet significantly 
increased body weight gain and melatonin treatment reversed the body weight gain as well as 
lowered blood glucose, cholesterol and triglyceride levels, consistent with previous studies  by 
Bartness et al. (2002) and Shieh et al. (2009) 
 
Although a wealth of data has accumulated on melatonin’s involvement in energy expenditure 
and body fat mass regulation (Prunet-Marcassus et al., 2003; Rasmussen et al.,1999; Alonso-
Vale et al., 2008; for reviews see Barrett  & Bolborea, 2012; Nduhirabandi et al., 2012, Cipolla-
Neto et al., 2014), the hypothesized anti-obesogenic effect of melatonin may in part be due to 
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its regulatory role on energy balance through activation of brown adipose tissue (BAT) (see 
below), thereby aiding in body weight regulation (for a review see Cipolla-Neto et al., 2014), 
however, the underlying mechanism of obesity and its related pathologies are complex and 
needs to be further investigated.  
 
 
1.8.3.2 Melatonin and brown adipose tissue (BAT) 
 
It is well established that obesity can be reduced by promoting energy expenditure. (Jimenez-
Aranda et al., 2013) While white adipose tissue (WAT) functions to store excess triglycerides 
(Ntambi & Young-Cheul, 2000) and positively correlates with increased fat mass, brown 
adipose tissue (BAT) has the ability to dissipate energy (ATP) by producing heat 
(thermogenesis) (Ginter & Simko, 2012; Jimenez-Aranda et al., 2013; Haas et al., 2012)  and 
is negatively correlated with body mass index (Benito, 2011).  
This physiological process is mediated by an important mitochondrial transporter protein, the 
uncoupling protein 1 (UCP1) (Zhou et al., 2014) and its upstream regulator, the peroxisome 
proliferator activated receptor gamma coactivator 1 (PGC1-α) (Zhou et al., 2014; Austin & St-
Pierre, 2012). 
Interest in white adipose tissue (WAT) led to the discovery of brown-like (‘beige’) adipocytes 
in WAT of animals and humans and it has been shown that browning of WAT can be induced 
with cold stimuli in animals (Jimenez-Aranda et al., 2013). 
Several investigators have shown that BAT activity can be increased with melatonin treatment 
(Holtorf et al., 1985; Jimenez-Aranda et al., 2013). In a recent study on the effects of melatonin 
on obesity, it was found that melatonin-treated obese rats displayed reductions in body weight 
mass with raised core body temperature, due to the direct regulatory actions of melatonin on 
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energy expenditure through its metabolism-activating effects in BAT and in the browning of 
WAT (Heldmaier et al., 1981; Tan et al., 2011; for a review see Cipolla-Neto et al., 2014). 
  
PGC1-α expression is reduced in insulin-resistant and diabetic humans, and PGC1-α-null mice 
has been shown to have skeletal and cardiac muscle contractility defects, possibly due to insulin 
resistant humans having fewer mitochondria in their muscles (for a review see Kim et al., 
2008). In a study by Jimenez-Aranda et al., 2013, it was shown that increased expression of 
PGC1-α was found in beige depots of lean melatonin-treated animals compared to the untreated 
obese animals (Jimenez-Aranda et al., 2013), suggesting that melatonin increased the activity 
of the ‘master regulator’ of thermogenesis, PGC1-α (Puigserver et al., 1998). 
 
With regard to the uncoupling proteins, UCP1 expression is unique to brown adipose tissue, 
UCP2 is ubiquitously expressed and UCP3 in skeletal and heart muscle. UCPs play a vital role 
in mitochondrial function by regulating heat and ROS generation (for a review see Kim et al., 
2008). In the same above-mentioned study, melatonin increased UCP1 expression in beige 
depots in diabetic rats where it was previously absent (Jimenez-Aranda et al., 2013; for a 
review see Cipollo-Neto et al., 2014). 
Melatonin treatment at 10 mg/kg/day also induced browning of WAT in both Zucker diabetic 
fatty (ZDF) and Zucker lean (ZL) rats. These effects of melatonin may be a part of the 
mechanisms associated with its anti-obesity and antidiabetic properties (Jimenez-Aranda et al., 
2013). 
 
1.8.3.3 Melatonin and insulin resistance  
 
Given the importance of melatonin in a range of physiological processes in the body and the 
widespread distribution of its receptors including in the pancreatic β-cells (McMullan et al., 
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2013), melatonin has been implicated in the regulation of insulin secretion and glucose 
metabolism (Nishida 2005; Peschke 2008). In this regard, in vivo studies have shown that 
melatonin administration leads to a significant reduction in insulin secretion (Rasmussen et al., 
1999; Wolden-Hanson et al., 2000) with similar findings in vitro (Picinato et al., 2002; 
Peschke, 2008).  
 
Frese and co-workers (2009) showed reduced endogenous melatonin synthesis in type 2 
diabetic (Goto-Kakizaki) rats while chronic melatonin administration of 2.5 mg/kg, daily 
enhanced plasma melatonin and reduced insulin levels in these animals (Peschke et al., 2010), 
similar to the above-mentioned in vitro and in vivo findings.  
 
In a high-fat/high-sucrose animal diet study, improvements of not only metabolic profile and 
oxidative stress status, but also increased insulin sensitivity and decreased blood glucose levels 
were evident using melatonin and its agonist, NEU-p11 (She et al., 2009). Interestingly, a 2 
week melatonin treatment of rats fed a high-fructose diet for 6 weeks showed no changes in 
body weight, however it ameliorated insulin resistance (Kitagawa et al., 2012; for a review see 
Nduhirabandi et al., 2012).  
In addition, melatonin supplementation in type 2 diabetic rats significantly reduced insulin 
levels and improved insulin sensitivity (McMullan et al., 2013). Furthermore, both short- and 
long-term melatonin consumption improved insulin sensitivity and glucose intolerance in type 
2 diabetic rats as well as in high-fat diet induced obesity rats (for a review see Nduhirabandi et 
al., 2012). 
 
Several studies have also employed pinealectomized rats for better insight into melatonin’s role 
in insulin resistance (Picinato et al., 2002; McMullan et al., 2013). For example, it has been 
reported that such rats exhibited glucose intolerance (impaired GLUT 4 expression), reduced 
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muscle and liver glycogenolysis, high blood glucose levels (Picinato et al., 2002) and  
decreased adipose tissue responsiveness to insulin (McMullan et al., 2013). On the contrary, 
hypoglycemia, restored GLUT-4 content and increases in glucose tolerance were noted after 
infusion of pineal extracts in rats (Picinato et al., 2002; Zanquetta et al., 2003). Experimental 
evidence also exist for melatonin and the autonomic nervous system output as facilitators of 
the master clock in regulation of circadian plasma glucose and insulin levels (Cailotto et al., 
2005, for a review see Cipolla-Neto et al., 2014). 
 
The mechanisms involved in the effect of melatonin on insulin resistance, are not yet fully 
understood. The insulin resistance cascade is associated with the coupling of insulin to the 
insulin receptor (IR), phosphorylation of the substrate proteins (IRS-1/2) and PI3-K, PKB/Akt 
and PKC activation. Melatonin treatment, on the other hand, is associated with stimulation of 
receptor-mediated signal transduction pathways, exerted through Gi protein-coupled receptors, 
MT1 and MT2 (Peschke et al., 2008). It has been reported that in rat pancreatic beta cells, 
melatonin exerts its effects via three intracellular pathways, namely the Gi-α dependent cyclic 
adenosine monophosphate (cAMP) pathway, cyclic guanosine monophosphate (cGMP) and 
Gi-α- Inositol 1,4,5-triphosphate (IP3) independent pathway (for reviews see Peschke et al., 
2008; Zanuto et al., 2013).  
 
Melatonin may interact with the insulin signalling cascade by activating the insulin receptor-
mediated PI3-K, PKB/Akt and the mitogen-activated extracellular signal-regulated kinase 
(MEK/ERK) pathway by tyrosine phosphorylation of IRS1 and 2 (Picinato et al., 2008).   
Melatonin also stimulates glycogen synthesis and increased phosphorylation of hepatic 
glycogen synthase kinase 3 β (GSK3-β) (Shieh et al., 2009; for a review see Nduhirabandi et 
al., 2012) 
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Even more so, the use of melatonin antagonist, luzindole, blocked the above-mentioned 
beneficial effects of melatonin, implying involvement of melatonin receptors in its metabolic 
actions (Ha et al., 2006).  
 
 
 
Figure 1.5 Effect of melatonin administration on hepatic glycogen synthesis and skeletal 
muscle glucose homeostasis (for a review see Nduhirabandi et al., 2012). 
Melatonin administration was associated with significant increases in hepatic glycogen 
synthesis and improved skeletal muscle glucose homeostasis by eNOs (endothelial nitric oxide 
synthase) activation. The effect of melatonin on IRS phosphorylation and glucose uptake has 
not been established. The mitogen activated protein kinase (MAPK) pathway was not included 
in the figure; IR, insulin receptor; IRS-1, insulin receptor substrate 1; PI-3K, 
phosphatidylinositol-3-kinase; PKC-ζ, protein kinase C-zeta; GSK-3b, glycogen synthase 
kinase-3 beta; GLUT-4, glucose transporter-4; Mel, melatonin; MT1/2, melatonin receptor 1, 
2; Ins, insulin. 
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1.8.4 Melatonin and the heart 
 
It is well-known that melatonin regulates many physiological processes in a circadian manner 
(Dominguez-Rodriguez et al., 2010). In addition, studies have reported that melatonin 
influences multiple factors of cardiovascular function (Tengattini et al., 2008). Moreover, 
receptors for melatonin have been identified in the cardiovascular system (Ekmekcioglu et al., 
2003).  
 
Under physiological conditions, heart function is unaffected by melatonin treatment (Patel et 
al., 2010; Nduhirabandi et al., 2011). However, profound effects on the heart were seen with 
chronic melatonin consumption including, a reduction in absolute and relative heart weight 
(Bojkova et al., 2008) and increased glycogen content (Kassayova et al., 2006).  Additionally, 
chronic melatonin treatment counteracted the heightened susceptibility of MPTP opening due 
to calcium overload (Petrosillo et al., 2009), plus improvements in myocardial hypertrophy 
were noted (Reiter et al., 2010).    
Further associations between melatonin and the heart were found in patients with coronary 
heart disease (CHD) or acute myocardial infarction (AMI) who exhibited low circulating levels 
of melatonin (Brugger et al., 1995). 
 
Another interesting association is the increased risk for stroke and myocardial infarction in the 
morning with coinciding low plasma circulating melatonin levels (Macchi & Bruce, 2004).  
Melatonin was also shown to influence blood pressure (Kitajima et al. 2001) and heart function 
(Abete et al.1997) directly and/or indirectly by influencing risk factors associated with heart 
disease such as increased visceral fat accumulation and dyslipidaemia (Agil et al. 2011, 
Kozirog et al. 2011, Nduhirabandi et al. 2011). 
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1.8.4.1 Melatonin and myocardial ischaemia/reperfusion injury 
 
The cardioprotective actions of melatonin on the ischaemic/reperfused heart are well-
established (for review see Nduhirabandi et al., 2012; Lochner et al., 2013; Reiter et al., 2003; 
Tengatini et al., 2008). 
It has been reported that melatonin has significant protective actions against the events that 
occur during ischaemia/reperfusion (I/R). In addition, pharmacological doses of melatonin both 
before ischaemia and/or after reperfusion reduced ventricular fibrillation and premature 
ventricular contractions associated with reperfusion and decreased arrhythmias (Tan et al., 
1998), possibly owing to melatonin’s free-radical scavenging actions (Lee et al., 2002; Sahna 
et al., 2002; for a review see Reiter & Tan, 2003).  
 Using confocal microscopy of live cardiomyocytes, Salie and coworkers (2001) showed that 
melatonin protected these cells against I/R damage by inhibition of ROS generation and 
intracellular Ca2+ accumulation.  Melatonin has also been shown to reduce myocardial infarct 
size (Sahna et al., 2002; Dobsak et al., 2003; Lochner et al., 2006) and improve functional 
recovery during reperfusion after ischaemia (Tengattini et al., 2008; for a review see Reiter & 
Tan, 2003). 
 
1.8.4.2 Melatonin-induced cardioprotection: RISK and SAFE pathways 
 
As mentioned previously, activation of prosurvival signalling pathways, at the time of 
reperfusion, is associated with limitation of reperfusion injury (Lacerda et al., 2009; Hausenloy 
& Yellon, 2008). 
These cardioprotective pathways include, the Reperfusion injury Salvage Kinase (RISK) 
pathway, (PKB/Akt and ERK 1/2) and the Survivor Activating Factor Enhancement (SAFE) 
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pathway (Genade et al., 2008; Lamont et al. 2011), which involves the Janus Kinase (JAK) 
activation and signal transducer and activation of transcription 3 (STAT-3) (Lecour, 2009).   
 
Genade et al. (2008) assessed the involvement of these prosurvival pathways in the presence 
and absence of melatonin, and found that under conditions of ischaemia, followed by 10 
minutes reperfusion and subsequent western blotting, PKB/Akt was phosphorylated/activated 
and the opposite was seen for the pro-apoptotic kinase p38 MAPK. Activation of this 
prosurvival pathways was seen regardless of whether melatonin was administered before or 
after ischaemia. Lamont et al (2011) reported that melatonin treatment induced activation of 
STAT3 prior to induction of ischaemia. Furthermore, melatonin elicited no protection against 
I/R injury in TNF-α receptor 2 and myocardial STAT-3 knockout mice, suggesting that 
activation of the SAFE pathway before the onset of ischaemia is important in cardioprotection. 
In both these studies activation of the survival pathways was associated with a significant 
reduction in infarct size. 
 
 
Interestingly, the dosage of melatonin administered  may not appear to be important in 
cardioprotection in this scenario. For example, Lamont et al. (2011) showed that hearts 
pretreated with melatonin in the picomolar range, exhibited a reduction in infarct size during 
reperfusion, However, most workers  made use of higher concentrations of melatonin, for 
example Lochner et al. (2006) and Genade et al. (2008) used melatonin at a concentration of 
50µM. 
 
Apart from this, cardioprotection associated with melatonin has been linked to melatonin 
receptors (MT1/2) that has been identified in the heart (Ekmekcioglu et al., 2003; Lochner et 
al., 2006). In addition, in a study on rats by Sallinen and coworkers (2007) on the effect of 
myocardial infarction and melatonin receptor expression, it was shown that post-myocardial 
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infarction, the animals had increased pineal melatonin synthesis, associated with raised plasma 
melatonin levels along with a consequent enhanced melatonin receptor expression. These 
results suggest an important role of endogenous melatonin plus its receptors after myocardial 
infarction (Sallinen et al., 2007). In support of this, Lochner et al. (2006), using the melatonin 
receptor antagonist luzindole, found that the cardioprotective effects of melatonin were 
abolished. 
  
As previously mentioned, the opening of the MPTP during myocardial reperfusion injury is 
associated with cell death. It was shown that melatonin inhibited this opening via prevention 
of mitochondrial cardiolipin peroxidation, thus associated with cardioprotection (Petrosillo et 
al., 2009; for a review see Lochner et al., 2013). 
 
Melatonin’s antioxidant, anti-inflammatory, anti-adrenergic activities as well as its ability to 
enhance antioxidant enzyme activities, have all been associated with its conferred 
cardioprotection (Genade et al., 2008; Dominguez-Rodriguez et al., 2010). 
Another interesting observation was made by administration of exogenous melatonin to 
pinealectomized animals which not only raised the level of circulating melatonin, but also 
maintained a high level up to 3 weeks after treatment (Djeridane et al., 2000), suggesting that 
the beneficial effects of melatonin treatment could last for days after treatment (Lochner et al., 
2006). These long-term effects of melatonin may be due upregulation of the melatonin 
receptors, since pretreatment of rats with a combination of melatonin and the melatonin 
receptor blocker, luzindole, abolished cardioprotection (Lochner & Genade, unpublished 
observations). However, further investigations are required for elucidation of these effects. 
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1.5 MOTIVATION FOR STUDY 
 
As stated before, obesity is currently considered as a global major health issue and risk factor 
for type 2 diabetes and cardiovascular disease, especially ischaemic heart disease (Eckel et al., 
2005; Emanuela et al., 2012).  
 
There is increasing evidence for the role of adipose tissue dysfunction, dysregulated 
adipocytokines and elevated free fatty acid release in promoting oxidative stress in obesity  
(Furukawa et al., 2004; for a review see Hajer et al., 2008). Furthermore, it is well-established 
that oxidative stress is associated with several pathological states, including heart disease and 
particularly damage to the ischaemic-reperfused myocardium (Opie, 2004; Yellon & 
Hausenloy, 2007). 
 
Melatonin is considered by many researchers as the ideal free radical scavenger and antioxidant 
(Reiter 1995; Tan et al., 2002; Hardeland et al., 2005). It has been shown to have marked 
beneficial effects in animal models of obesity (Prunet-Marcassus et al., 2003; Hussein et al., 
2007; Shieh et al., 2009) and to protect the heart against ischaemia/reperfusion injury (Salie et 
al., 2001; Tengattini et al., 2008; Petrosillo et al., 2009; Nduhirabandi et al., 2011) suggesting 
a potential role for melatonin in both obesity management and cardioprotection.   
Nduhirabandi and coworkers (2011 & 2014) previously showed that melatonin treatment 
reduced infarct size in both control and obese rats. However, in view of the obesity paradox, it 
is not known how melatonin treatment will affect cardioprotection. Interestingly, melatonin 
abrogates protection induced by prior preconditioning, due to its free radical scavenging 
properties (Genade et al., 2006). In this context melatonin may affect diet-induced resistance 
to ischaemia/reperfusion injury and thus exploration of melatonin effects in models of obesity 
remains important. 
 
Stellenbosch University  https://scholar.sun.ac.za
47 
 
A previous study in our laboratory made use of a hyperphagia-induced rat model of obesity, 
achieved by adding excess sucrose to the diet. However, the changes induced by this diet were 
relatively small and the animals, despite becoming insulin-resistant, did not develop type 2 
diabetes. It was therefore decided to adjust the diet by adding cooking fat to the sucrose diet in 
the hope that this will induce more marked changes in the myocardium, leading to, amongst 
others, myocardial hypertrophy and type 2 diabetes. 
 
We hypothesize that melatonin, in view of its free radical scavenging properties, may alter the 
response of the heart to obesity-induced cardioprotection. This, of course, is based on the 
assumption that the high fat diet will elicit the obesity paradox. 
 
The aims of this study were therefore: 
(i) To evaluate the ability of a high fat diet (HFD) to induce obesity in rats. Apart from 
evaluating its effects on the biometric parameters and resistance to 
ischaemia/reperfusion injury (as indicated by infarct size in regional ischaemia and 
functional recovery after global ischaemia), special attention will be given on the 
interplay between adiponectin, AMPK, leptin, and FFA in this model.  
(ii) To evaluate the effect of daily oral administration of melatonin to rats on the HFD as 
well as their littermate controls, on the parameters listed above as well as on the 
development of obesity. In this study melatonin will be administered from the onset of 
the feeding of the high fat diet. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1    ANIMAL CARE AND ETHICS 
 
96 Male Wistar rats (weighing ±200g) were obtained from the University of Stellenbosch 
Central Research Facility. The milieu in which the animals were maintained included 
controlled conditions of a 12-h dark/light setting with lights on from 6:00 am until 6:00 pm, 
with constant temperature (22°C) and humidity (40%). Ethical clearance was obtained from 
the Committee for Ethical Research: Animal Care and Use, University of Stellenbosch (SU-
ACUM13-00035). Animals were treated according to the guidelines of the South African 
National Standard for the Care and Use of Animals for Scientific Purpose (SANS 10386:2008).   
 
 
2.2 EXPERIMENTAL DESIGN 
 
The study consisted of three parts. The first part included grouping, feeding and treatment. For 
the second part, biometric measurements (body weight, visceral fat etc.), blood collection (for 
analyses of blood glucose, plasma insulin, leptin, adiponectin, free fatty acids , triglycerides, 
cholesterol, phospholipids, conjugated dienes and thiobarbituric acid  reactive substances 
(TBARS) as well as heart tissue excision and perfusions were performed. Lastly, biochemical 
determinations of blood and heart tissue collections were carried out.  
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2.2.1 Feeding and treatment 
 
Male Wistar rats (200±20 g) were divided into four groups (24 each) consisting of: group C 
(control) which received standard rat chow and drinking water; group C+M (control + 
melatonin) received a standard rat chow with melatonin in the drinking water; group HFD, 
received a high-fat diet (HFD) with normal drinking water and lastly, group HFD+M received 
a high-fat diet (HFD) with melatonin in the drinking water. The feeding and treatment were 
initiated simultaneously and lasted for 16 weeks with fresh food/water given daily to all of the 
above mentioned groups. The high fat diet was prepared as follows: normal rat chow (2.4Kg); 
sugar (520g); condensed milk (full cream) 8 cans; Holsum cooking fat (550g); water (2L). 
The compostion of the control rat chow and the HFD is summarized in Table 1. 
 
Table 1.  Composition of the diets 
       Control rat chow   HFD 
Total fat (g/100g)      4.8    11.5 
Saturated fat (g/100g)  0.9    7.6 
Cholesterol (mg/100g) 2.2    13 
%Protein   17.1    8.3 
%Carbohydrate  34.6    42 
Sucrose   5.3    20.4  
Analysis of the diets was done by Microsept, Cape Town 
 
2.2.2 Melatonin administration 
 
Melatonin (Sigma Aldrich, St Louis, MO, USA), was first dissolved in 1 ml of absolute ethanol 
and added to 1L drinking water (ethanol concentration 0.1% (v/v)). The final concentration of 
melatonin in the drinking water was 75µg/ml or 50µg/ml for the HFD and control rats 
respectively. These amounts were based on the daily fluid intakes of the HFD and control 
animals to obtain a dosage of 10mg/kg/day.  The animals were weighed on a regular basis (once 
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a month) and the amounts of melatonin added to the drinking water adjusted so that the dosage 
of 10mg/kg/day was maintained throughout the experimental period. Since melatonin is light 
sensitive, the bottles containing the melatonin water were covered with aluminium foil. Water, 
melatonin and food were available ad libitum. Drinking water with or without melatonin was 
replaced every day one hour before light off as previously indicated (Wolden-Hanson et al., 
2000; Prunet-Marcassus et al., 2003). The melatonin solution was prepared freshly every 2 
days and stored in a refrigerator at 4ºC until used. 
 
2.3 EXPERIMENTAL PROTOCOL 
 
Following the 16 week period of feeding and treatment, the animals were grouped into non-
fasted and overnight fasted (for baseline measurements). They were then anaesthetized by 
intraperitoneal injection of 30mg/kg pentobarbital, body weights were determined, blood 
glucose levels measured (from tail tip) and then sacrificed. The excision of the heart was 
followed by blood collection from the thoracic cavity as well as collection and weighing of 
visceral fat. Blood samples were centrifuged at 3000rpm (4o C), the plasma collected and kept 
frozen at -80o C until analyses were done. The hearts were either perfused (non-fasted) or 
freeze-clamped (fasted). For each rat the adiposity index was calculated (ratio of visceral fat 
mass to body weight multiplied by 100). 
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Figure 2.1 After excision, the heart was mounted onto the aortic cannula, followed by 
insertion of the atrial cannula into the pulmonary vein (Lochner A, BHons lectures, 2013). 
 
2.3.1 Perfusion technique 
 
Figure 2.2 Perfusion apparatus for working rat hearts (Neely et al., 1967). 
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Following removal of the rat heart, it was placed into ice-cold Krebs-Henseleit solution for 
arrest and then mounted via the aorta onto the aortic cannula and tied with a silk suture as 
demonstrated in fig 2.1. The hearts were perfused with Krebs-Henseleit buffer containing (in 
mM): NaCl 119, NaHCO3 24.9, KCl 4.7, KH2PO4 1.2, MgSO4.7H20 0.59, Na2SO4 0.59, 
CaCl2.H2O1.25 and glucose 10. The buffer was gassed with 95%O2/5%CO2 to obtain a pH of 
7.4. For stabilization, the hearts were retrogradely perfused (Langendorff mode), in a non-
recirculating manner (at 100 cm H2O) for 15 minutes, followed by 15 minutes of atrial 
perfusion, in the working heart mode, at a preload of 15cm H2O and afterload of 100cm H2O 
(see fig 2.1). 
 The hearts were then subjected to either  (i) global ischaemia or (ii) regional ischaemia induced 
by ligation of the left descending coronary artery (see fig 2.3.2 (i/ii)). The temperature of the 
hearts was monitored by inserting a temperature probe into the pulmonary artery and kept at 
constant temperatures of 37°C and 36.5°C, during perfusion and ischaemia, respectively. 
Manual measurements of coronary flow (CF) and aortic output (AO) were made before and 
after ischaemia while the heart was perfused in the working mode, while a Viggo-Spectramed 
pressure transducer inserted into the aortic cannula, coupled to a computer system, was used to 
measure the aortic pressure (systolic/diastolic (mmHg)) and heart rate (HR in beats per minute, 
bpm).   
 
Total work performance (pressure power) was calculated according to the formula of 
Kannengieser et al. (1975):  
0.002222(PAO -11.25).(CO) 
Where, PAO  = aortic pressure 
 CO =cardiac output (aortic output +coronary flow rate) 
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For each heart, the recovery of function during reperfusion was calculated for each parameter 
by expressing function during reperfusion as a percentage of function before induction of 
ischaemia. 
 
 
 
 
 
 
 
 
Figure 2.3.1 Experimental approach: Four groups of animals were studied.  In each group 
biometric measurements were made and blood collected for biochemical analyses collected. 
Hearts were then removed for perfusion for measurement of functional performance, infarct 
size and collection of tissue for Western blotting. 
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2.3.1.1 Regional and global ischaemia 
 
Following the stabilization period, regional ischaemia was induced by occlusion of the left 
anterior descending coronary artery (LAD) with a silk suture (inserted and tied below the LAD) 
for 35 minutes at 36.5°C. A reduction of 33% in coronary flow signified sufficient regional 
ischaemia. Once the 35 minutes had elapsed, the silk suture was removed and the  
hearts perfused for an additional 60 minutes (10 min retrograde, 20 min working mode, 30 min 
retrograde) after which infarct size was determined. Mechanical function was measured before 
and after induction of ischaemia during perfusion in the working mode. See Fig 2.3.2 (i). 
For global ischaemia, the same stabilization period was used; however, thereafter, the aortic 
cannula was completely occluded resulting in no flow to the heart (no-flow ischaemia) for 20 
minutes at 36.5°C. To reperfuse the aortic cannula was reopened and the hearts were perfused 
for 30 minutes (10 min retrograde; 20 min working mode) for determination of function. At 
the end of reperfusion, hearts were freeze-clamped and stored in liquid nitrogen for subsequent 
biochemical analysis.  A similar intervention was performed for determination of kinase 
activity with freeze-clamping of the hearts after 10 minutes of reperfusion following global 
ischaemia (20 minutes). See Fig 2.3.2 (ii). 
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(i)          Stabilisation              Regional Ischaemia              Reperfusion 
                                                       
                                                                                                                                         
              LD         WH                                              LD        WH                                                                                                        
        
          0              15         30                                65        75                95                          125  
                                               Time (in minutes) 
                                                                                                                                                     Infarct size 
(ii)           Stabilisation         Global Ischaemia   Reperfusion                                                 Western blotting 
                                                                                                                            
 
                   LD       WH                                    LD          WH                         
                                                   
Figure 2.3.2 Perfusion protocol: (i) Regional ischaemia (ii) Global ischaemia with infarct 
size and mechanical function (recovery) respectively as endpoints. 
 
2.3.1.2 Determination of area at risk and infarct size 
 
At the end of the perfusion protocol, the coronary artery was tied (with the silk suture) and 1ml 
of 0.5% Evans blue injected via the aorta cannula. Following over-night freezing of the hearts, 
they were cut into 2mm slices,  then stained for 15 minutes with 1% w/v triphenyl tetrazolium 
chloride (TTC) in phosphate buffer (pH 7.4) at 37°C. Thereafter, the slices were fixed in 10% 
v/v formaldehyde solution which enabled the distinction between viable tissue (indicated by 
the blue area), non-viable/infarcted tissue (the white (unstained) area) and the area at risk which 
constitutes the white area as well as the red area surrounding it. All slices were drawn on 
transparencies and then scanned to determine the area at risk (AR) and area of infarcted tissue, 
15 15 35 10 20 30 
15 15 10 20 10 20 
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using the UTHCSA (University of Texas Health Science Center at San Antonio, TX, USA) 
Image Tool software.  Infarct size (IFS) was expressed as a percentage of the area at risk 
(IFS/AR %). 
 
 
2.4 BIOCHEMICAL ANALYSES 
 
2.4.1 Western Blotting 
 
2.4.1.1. Tissue collection and lysates preparation 
 
Hearts were freeze-clamped either without perfusion (baseline conditions) or after 10 or 30 min 
reperfusion (see protocol fig 2.3.1). The tissues were stored at -800C until preparation of 
lysates. 
The lysis buffer consisted of (in mM): Tris-HCl 20, p-nitrophenylphosphate 20, EGTA 1, 
EDTA 1, NaCl 150, tetra-sodium-pyrophosphate 2.5, β-glycerophosphate 1, sodium 
orthovanadate 1, phenylmethyl sulphonyl fluoride 1, aprotinin and leupeptin both at 10µg/ml 
and Triton-X100 1%. The frozen tissue was pulverized and homogenized in 600-900 µl of lysis 
buffer using a Polytron homogenizer. Following centrifugation (1000xg for 10 minutes) of the 
samples, the supernatant was collected and diluted according to the lysates preparation 
protocol. The amount of protein in the lysate was determined using the Bradford technique 
(1976), using a standard curve of known BSA concentration to obtain the concentration of the 
unknowns. The lysis buffer and protein samples were then diluted in 3X Laemmli sample 
buffer to a final concentration of 50 µg of protein per 15 µl for loading into each well of the 
PAGE. The final lysates were then boiled for 5 min and stored at -20°C.  
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For STAT-3 lysates preparation, the same procedure was followed except that the frozen tissue 
was homogenized in lysis buffer without the addition of Triton-X100 1%. Following 
centrifugation at 14500 rpm for 10 minutes the supernatant was collected as the cytosolic 
fraction. The pellet was then resuspended in lysis buffer (600-900 µl) containing Triton-X100 
(1%) of which its supernatant (after additional centrifugation) was used for the nuclear fraction. 
The same procedure was followed to prepare the final lysates.                                                                            
 
 
2.4.1.2 Western blot technique 
 
After boiling and centrifugation of the lysates (for 5 minutes each), the protein was separated 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using a Bio-
Rad® mini-Protean III system. Either 10% (for AMPK, JNK, STAT-3 and UCP) or 12% (for 
PKB/Akt, ERK1/2 and PGC1-α) resolving gels (matrix to contain and separate molecules) 
were prepared with a 4% stacking gel on top of the resolving gel. The samples were loaded 
into the wells of the gels along with a commercial molecular weight marker/ladder (used to 
approximate the size of the protein separated on the gels) and placed into running buffer 
containing Tris 25 mM, glycine 192 mM and 0.1% SDS). After the separation process, proteins 
were transferred to PVDF membranes using transfer buffer (Tris 25 mM, glycine 192 mM and 
methanol (20% v/v) and then washed in methanol and allowed to air-dry. Once dried, the 
membranes were stained with Ponceau red reversible stain for confirmation of adequate protein 
transfer. The membranes were scanned using a ChemiDoc MP imaging system for later 
normalization. Blocking of non-specific sites on the membrane with 5% fat-free milk powder 
TBS-T solution (for 1 to 2 hours) or 5% Bovine serum albumin (BSA) in TBS-T (for UCP3 
and PGC1-α) required thorough washing of the membrane before and after with Tris-buffered 
saline plus 0.1% Tween 20 (TBS-T). The membranes were then incubated overnight in primary 
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antibody (5µl antibody in 5ml of TBS-T or 5% milk-TBS-T) at 4°C. Thereafter, the membranes 
were washed (at least 3 times for 5 minutes) with TBS-T and incubated in horse-radish 
peroxidase coupled secondary antibody (5µl antibody in 20ml TBS-T or 5% milk-TBS-T). The 
secondary antibody was then washed off using the same washing procedure as mentioned 
above. The details regarding the blotting technique and the preparation of the gels are 
summarized in tables 2 and 3.     
 
2.4.1.3 Western Blot detection and validation 
 
After washing, a detection reagent, Enhanced chemiluminescence (ECL), was used to detect 
the protein of interest. This was achieved using the ChemiDoc MP imaging system (Bio-Rad®). 
Normalization and analysis of data involved using the stored image of the Ponceau stained 
membrane  and  superimposing it on the image obtained from the antibody detection step. This 
results in a ratio of the signal from the protein-antibody reaction to the total protein in a specific 
lane. 
 
2.4.2 Western blot analysis  
Table 2- Western blot information table 
Protein 
Molecular 
weight (kDa) 
Resolving 
gel % 
Blocking time 
(hours)  1° Ab dilution 2° Ab dilution 
 
  Total Phosphorylated  
 
1:4000 5% milk 
(p-AMPK) 
PKB/Akt 60 12 1 2 1:1000 TBS-T 
ERK ½ 42/44 12 1 1h30 1:1000 TBS-T 
JNK 43-47 10 1h30 2+ 1:1000 TBS-T 
AMPK 62 10 1h30 2 1.5:1000 TBS-T 
PGC1-α 90 12 1  1 1:1000 TBS-T  
UCP 30-34 10 1 1  1:1000 TBS-T 
STAT-3 86-90 10 1h30 1h30 1:1000 TBS-T 
 
 
 
All       
1: 4000 
TBS-T  
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Table 3- Preparation of SDS-PAGE gels 
Reagents Stock Resolving gels Stack gel 
4% 10% 12% 
Distilled H2O  4.9 ml 3.35 ml 3.05 ml 
Tris 
pH8.8(gel)/pH6.8(stack) 
1.5 M / 0.5 M 250µl (1.5M) 250µl (1.5M) 1.25 ml (0.5M) 
SDS 10% 100 µl 100 µl 50 µl 
Acrylamide 40% 2.5 ml 3 ml 0.5 ml 
APS (0.1g in 1ml dH20) 10% 50 µl 50 µl 50 µl 
TEMED 99% 20 µl 20 µl 10 µl 
 
 
2.5.    BLOOD ANALYSIS 
2.5.1 Blood collection 
After excision of the hearts, blood collected from the thoracic cavity was placed in  K3-EDTA 
(Greiner bio-one™) tubes and kept on ice until centrifugation at 3000 rpm for 10 minutes at 
4°C (within 30 minutes of collection). The plasma was stored in Eppendorf tubes at -80°C until 
required for analyses.   
 
2.5.2 Blood glucose determination 
Blood samples were collected from the tip of the rat’s tail (before sacrifice) for measuring 
blood glucose levels using disposale test strips inserted into the GlucoPlus™ meter (CIPLA 
DIBCARE, Bellville, South Africa) afterwhich the reading was displayed in mmol/L.  
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2.5.3 Free Fatty Acid Quantitation assay 
Plasma FFA levels were measured using the Free fatty acid quantitation kit MAK044 (Sigma-
Aldrich®, St Louis, MO) in which the fatty acid concentration was determined by a coupled 
enzyme assay resulting in a colorimetric product  proportional  to the fatty acids present in the 
samples. 
Palmitic acid standards containing 0 (blank), 2, 4, 6, 8, and 10 nmoles/well were placed in the 
96 well plate provided. For the reaction wells, plasma samples (50µl) were pipetted directly 
into the wells. All standard and plasma samples were prepared in duplicate. Thereafter, 2 µl 
of  acyl-CoA synthetase  (ACS reagent) was added to all the wells and incubated (30 minutes 
at 37°C). Thereafter a master reaction mix containing a fatty acid probe was prepared and 
added to each well (50 µl/well). The plate was covered, shaken and incubated under the same 
conditions as above. The absorbance at 570nm was measured using a plate-reader (FLUOstar 
Omega, BMG Labtech. The blank reading was subtracted from all other values obtained after 
which a standard curve (for palmitic acid standard) was plotted and the fatty acid 
concentration of the samples (unknown) calculated from the curve.  
 
 
2.5.4 Leptin assay 
The leptin rat ELISA (enzyme-linked immunosorbent assay) kit (ab100773, abcam®) was used 
for measurement of plasma leptin levels.  This assay employs an antibody specific for leptin 
coated on a 96 well plate. Standards (prepared according to the manufacturer’s instructions) 
and samples were pipetted into the wells and the leptin present binds to the immobilized 
antibody on the wells. The wells were washed and biotinylated anti-rat leptin antibody added. 
After washing the unbound biotinylated antibody, HRP-conjugated streptavidin was added to 
the wells. The wells were again washed, a Tetramethylbenzidine (TMB) substrate solution was 
added and a colour developed in proportion to the amount of leptin bound. The stop solution 
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changed the colour from blue to yellow, the intensity of which is measured at 450nm on a plate 
reader. The assay procedure was carried out according to the company’s instructions and the 
concentration of leptin in the plasma samples were calculated from the standard curve.  
 
2.5.5 Adiponectin assay 
The adiponectin rat ELISA, ab108784 (abcam®) was used to detect its levels in plasma 
samples. This assay employs a quantitative sandwich enzyme immunoassay technique. 
Briefly, all reagents, standards (serially diluted) and samples were prepared according to the 
instruction booklet. Firstly, 50 µl of standards or samples were added to the 96 well plate 
(coated with a polyclonal antibody specific for rat adiponectin), with 1 hour incubation at 
room temperature, followed by addition of 50 µl biotin antibody (1 hour incubation), 50 µl 
streptavidin-peroxidase conjugate (30 minute incubation), 50 µl of chromagen substrate (10 
minutes incubation) until a blue colour developed. A 5 times wash step with wash buffer was 
done before and after every addition, following the incubation of samples and standards. 
Lastly, 50 µl of stop solution was added to the wells. The absorbance at 450 nm was read 
with a plate reader and a standard curve generated to determine the unknown sample 
concentration, multiplied by the dilution factor (plasma samples were diluted 400x). 
 
2.5.6 Insulin Assay 
Fasting plasma was collected as described previously (see 2.5.1). The Coat-A-Count® Insulin 
radioimmunoassay was used for the quantitative measurement of plasma insulin levels. 
Briefly, four uncoated polypropylene tubes were labelled for total counts (T) and non-specific 
binding (NSB), in duplicate, to which 200 µl of zero calibrator A was added. Fourteen insulin 
antibody-coated tubes A-G (with 200 µl of calibrators (standards) A-G added to respective 
tubes) as well as 200 µl of plasma samples were added to prepared tubes (in duplicate).  
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125I insulin (1 ml) was added to all tubes and incubated for 18-24 hours at room temperature. 
Following incubation, the tubes were decanted and all visible moisture removed. A gamma 
counter (Perkin Elmer WIZARD) was then used to count the radioacivity. The insulin levels 
of the samples were obtained from the standard curve. To assess insulin sensitivity/resistance, 
the homeostatic model assessment (HOMA-IR) index was calculated as follows: 
(fasting glucose concentration (mmol/l) x fasting insulin concentration (µIU/ml)) divided by 
22.5. 
 
2.5.7 Lipid Assay 
Lipid peroxidation, total cholesterol (TC), triglycerides (TG) and phospholipids (PL) were 
assayed for, using fasting plasma samples  and enzymatic colorimetric kits (KAT Medicals, 
Calicom Trading (PTY), South Africa; WAKO Chemicals, Germany) by a Labsystems 
Multiskan MS analyzer (AEC Amersham Co., South Africa). 
Plasma conjugate dienes (CD) and thiobarbituric acid reactive substances (TBARS) levels 
were determined spectrophotometrically by (i) initially mixing plasma samples with 
cyclohexane (Spectrosol) (Pryor and Castle, 1984; Esterbauer et al., 1989), followed by 
centrifugation at 14000 × g at 10°C, for 10 min. Thereafter, the absorbance of CD was 
measured at 234 nm using a GBC UV/VIS analyser (Wirsam Scientific and Precision 
Equipment, South Africa).  
(ii) TBARS were measured according to the method of Jentzsch et al (1996). The samples 
(200 µl) were mixed with 25µl  butylated hydroxytoluene (BHT) (Fluka Chemie, 
Switzerland) in ethanol (Merck Chemicals, South Africa) and orthophosphoric acid (Sigma 
Chemical Co) buffer at pH 3.6 and then vortexed for 10 seconds. Thereafter, 25 µL 
thiobarbituric acid (TBA) (Sigma) reagent was added to the mixture with subsequent 
vortexing, followed by a 45 min incubation (at 90ºC) in a water bath, after which the tubes 
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were placed on ice to stop the reaction.TBARS were extracted using n-butanol followed by 
addition of saturated NaCl and centrifugation at 12000 rpm for 1min. Lastly, absorbance was 
read at 532 nm using Labsystems Multiskan MS Analyser (AEC Amersham Co., South 
Africa). To determine LOOH, plasma was assayed in the presence of xylenol orange (3,3’-
bis[N,N-di(carboxymethyl)-aminomethyl]-o-cresolsulfonephtalein (Sigma Chemical Co) and 
Fe2+ in the ferrous oxidation/xylenol orange (FOX) assay that was adapted to enhance the 
solubility of non-polar compounds by including chloroform. Absorbance of the resulting 
Fe3+-xylenol orange complex was measured at 560nm (Jiang et al., 1991; Jiang et al., 1992) 
using Labsystems Multiskan MS Analyser (AEC Amersham Co., RSA). 
The final concentrations were then calculated using appropriate molar extinction, coefficients 
and standards. 
 
 
2.6 DATA ANALYSIS 
The data was analysed using GraphPad Prism software. All values were expressed as mean ± 
standard error of mean (SEM). The unpaired Student’s t-test was used for comparison of the 
control and high-fat diet groups. In most cases a one way analysis of variance (ANOVA) was 
used for multiple comparisons along with the Bonferroni correction. A two way ANOVA was 
used where appropriate. A p-value (calculated probability) of less than 0.05 was regarded as 
significant.  
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CHAPTER 3   
 
RESULTS 
 
3.1 BIOMETRIC AND METABOLIC DATA 
 
3.1.1 Characteristics of the 16 week high-fat diet model of obesity 
 
Over a period of 16 weeks feeding of the high fat diet (HFD) to rats caused significant increases 
in body weight (30.5%), visceral fat (80.7%) and adiposity index (39.8%) (Table 3-1) 
compared to their age-matched controls (fig 3-1 A & B). Fasted blood glucose levels of the 
diet fed group (11.05±1.093 mmol/L, p<0.005), plasma insulin (47.66 ± 6.835 µlU/mL, 
p<0.005) and HOMA index (24.33 ± 4.634, p<0.005) were significantly higher than their 
respective controls (fig 3-2 A, B & C, respectively; Table 3-1). 
Plasma leptin levels of the controls (5.060 ± 1.571 ng/mL) were significantly elevated by the 
diet to 10.84 ± 1.63 ng/mL, p<0.05 (fig 3-3 A). Compared to the controls, the HFD rats showed 
significantly lower adiponectin levels (HFD: 77.58 ± 3.79 ng/mL vs C: 109.2 ± 11.86 ng/mL, 
p<0.05) (fig 3-3 B; Table 3-1).  
Significant changes in the lipid profile were seen in the high-fat group. Plasma free fatty acids 
(FFA) (0.261 ± 0.058 mM, p<0.05) (fig 3-4 A), triglyceride (1.320 ± 0.45 mmol/L, p<0.05) 
(fig 3-4 B) and phospholipid levels (3.15 ± 2.33 mmol/L, p<0.05) were significantly higher 
than those of their control counterparts (see Table 3-2).   
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Figure 3-1 Impact of high-fat diet on (A) Body weight, **p<0.0001 (B) Visceral fat 
(n=16/group), ***p<0.001 vs C 
 
A B 
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Figure 3-2 Effect of diet on (A) Fasted blood glucose, **p<0.01 (B) Plasma insulin, 
p<0.01 (C) HOMA index (n=8/group), **p<0.005 vs C 
A 
B 
C 
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Figure 3-3 Effect of diet on (A) Plasma leptin (n=6-7) and (B) Plasma adiponectin (n=7), 
*p<0.05 vs C    
 
 
 
 
 
Figure 3-4 Effect of diet on (A) Plasma free fatty acids (n=8) and Triglyceride (n=6), 
*p<0.05 vs C 
 
 
 
 
 
A B 
  
 * 
Stellenbosch University  https://scholar.sun.ac.za
68 
 
3.1.2 Effects of chronic melatonin intake on control and high-fat diet animals 
Chronic melatonin consumption (16 weeks) significantly reduced body weight by 10.7% in 
control [342 ± 8(C+M) vs 384± 6g (C), p<0.05] and 22.8% in high-fat diet groups [387± 12 
(HFD+M) vs 500± 9g (HFD), p<0.001] (fig 3-5 A). The intake of melatonin was also 
associated with reductions in visceral fat mass in both control (9.050 ± 0.8 vs 11.27 ± 0.99 g) 
and fat (15 ± 1.09 vs 20.37 ± 1.61 g, p<0.05) fed groups (fig 3-5 B). Melatonin significantly 
reduced blood glucose [11.05 ± 1.09 (HFD) vs 6.88 ± 0.55 mmol/L (HFD+M), p<0.005], 
HOMA index [24.33 ± 4.63 (HFD) vs 9.8 ± 2.43 (HFD+M)] (fig 3-6 A & C) and leptin [10.84 
± 1.63 (HFD) vs 5.86 ± 0.61 ng/mL (HFD+M), p<0.05] (fig 3-7 A) levels of rats receiving the 
high-fat diet, without having a significant effect on the controls. Melatonin had no significant 
effect plasma adiponectin (fig 3-7 B), free fatty acid (fig 3-8 A) and triglyceride (fig 3-8 B) 
levels in animals receiving standard rat chow or the high-fat diet. Although melatonin had no 
effect on plasma insulin levels of the control group, it caused a significant reduction in the 
plasma insulin levels of the HFD group (P=0.05, when using a two way ANOVA). Plasma CD 
and TBARS levels of both control and HFD rats were not affected by melatonin (Table 3-2). 
Table 3-1 Biometric and metabolic parameters 
Parameters C HFD C+M HFD+M n 
Body weight (g) 384 ± 6 501 ± 9*** 342± 8 * 387± 12 ### 16 
Visceral fat (g) 11.27 ± 0.99 20.37 ± 1.6 *** 9.05 ± 0.80 15 ± 1.09 # 16 
Adiposity index 2.94 ± 0.25 4.11 ± 0.349 * 2.556 ± 0.21 3.87 ± 0.25 16 
Blood glucose (mmol/L) 6.96 ± 0.58 11.05 ± 1.09 ** 5.78 ± 0.3 6.9 ± 0.55 ## 8 
Plasma insulin (ulU/mL) 17.6 ± 5.16 47.7 ± 6.835 ** 17.51 ± 2.7 29.71 ± 5.43 8 
HOMA index 5.82 ± 2.09 24.33 ± 4.634 ** 4.38 ± 0.66 9.8 ± 2.43 # 8 
Plasma leptin 
(ng/mL) 
5.06 ± 1.57 10.84 ± 1.63 * 3.28 ± 0.55 5.86 ± 0.61 # 6-7 
Plama adiponectin 
(ng/mL) 
109.20 ± 11.86 77.58 ± 3.98 * 90.51 ± 4.83 67.00 ± 3.13 7 
*p<0.05, **p<0.005, ***p<0.0001 vs C and #p<0.05, ## p<0.005 ###p<0.001vs HFD 
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Figure 3-5 Effect of chronic melatonin treatment on (A) Body weight (B) Visceral fat.  
*p<0.05, ***p<0.0001 vs C and #p<0.05, ###p<0.001 vs HFD, (n=16/group) 
A B 
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Figure 3-6 Effect of melatonin treatment on (A) Fasted Blood glucose, (B) Plasma 
insulin and (C) Homeostasis model assessment (HOMA) index.  **, ***p<0.005 vs C, 
and # p<0.05, ##p<0.005 vs HFD, (n=8/group).   
 
A 
B 
C 
Stellenbosch University  https://scholar.sun.ac.za
71 
 
 
 
Figure 3-7 Effect of melatonin treatment on (A) Plasma leptin (n=6-7) and Plasma 
adiponectin (n=7), *p<0.05 vs C, #p<0.05 vs HFD 
 
 
 
 
 
 
 
Figure 3-8 Effect of melatonin treatment on (A) Plasma free fatty acids (n=8) and 
Triglyceride (n=6), *p<0.05 vs C 
 
 
 
A B 
* 
* 
A B 
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Table 3-2 Impact of diet and treatment on plasma lipid profile: Plasma free fatty acids (FFA) (n=8), 
Total cholesterol (TC) (n=6), Triglyceride (TG) (n=6), Phospholipids (PL) (n=6), Conjugated dienes 
(CD) and CD (n) (n=6), TBARS and TBARS (n) (n=2), *p<0.05 vs C. CD (n) and TBARS (n): values 
were normalized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group FFA (mM) 
TG 
(mmol/L) 
TC 
(mmol/L) 
PL 
(mmol/L) 
CD 
(µmol/L) 
TBARS 
(µmol/L) 
CD 
n 
(µmol/ 
mmol) 
TBARS 
n 
(µmol/ 
mmol) 
C 0.097±0.026 0.73±0.32 1.66±0.44 1.64±0.59 33.21±13.78 12.17±0.34 16.01±9.73 6.02±1.29 
HFD 0.26±0.058* 1.32±0.45* 1.31±0.31 3.15±2.33 36.19±12.36 15.35±2.62 7.35±2.43 5.01±5.49 
C+M 0.21±0.035 0.70±0.13 1.52±0.30 1.56±0.54 27.74±11.43 14.74±2.89 12.86±5.35 6.58±2.56 
HFD+
M 0.318±0.07 1.24±0.39 1.48±0.48 2.39±1.25 30.74±12.13 13.54±1.41 8.99±3.39 3.18±0.84 
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3.2 EFFECT OF DIET AND TREATMENT ON MYOCARDIAL INFARCT SIZE AND 
FUNCTIONAL RECOVERY 
 
3.2.1 REGIONAL ISCHAEMIA 
 
To evaluate the effect of the diet and melatonin administration on myocardial functional 
recovery and infarct size, after a stabilization period of 30 min hearts were subjected to 35 
minutes of regional ischaemia followed by 30 minutes of reperfusion, at which point functional 
recovery was evaluated. The hearts were then perfused for an additional 30 minutes after which 
time infarct size (total reperfusion time: 60 minutes) was determined. 
The high-fat diet had no significant effect on myocardial infarct size when compared to those 
of rats on the control diet (fig 3-9). However, daily administration of melatonin significantly 
reduced the size of infarction in both control [% of area at risk: 20.59 ± 2.29 (C+M) vs 38.08 
± 2.77 (C) and high-fat diet groups [% of area at risk: 11.43 ± 2.94 (HFD+M) vs 38.06 ± 3.59 
(HFD)] (fig 3-9 B). In addition, a significant difference between the control and HFD 
melatonin-treated groups were noted [20.59 ± 2.29 (C+M) vs 11.43 ± 2.94 (HFD+M)]. 
The area at risk was  similar for all groups averaging at 45.18 ± 1.137% for C, 48.24 ± 2.7% 
for HFD, 45.89 ± 1.68% for C+M and 45.37 ± 1.68% for HFD+M. Additionally, fig 3-10 
represents functional recovery [aortic output (A), cardiac output (B) and total work (C)] 
before ischaemia [A(i), B(i) and C (i)] and after reperfusion [A(ii), B(ii), C (ii)]. Evaluation 
of myocardial performance of hearts from control and HFD rats showed that the diet had no 
effect on any of the parameters of mechanical function when measured during perfusion 
under control conditions. Hearts subjected to 35 min regional ischaemia exhibited a profound 
effect on functional performance during reperfusion. In both control and HFD groups all 
parameters measured (except for heart rate where no significant changes were observed) were 
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significantly lower than their corresponding control values (p<0.001). Interestingly, no 
significant differences were seen between the two groups (Table 3-3 A). Similar observations 
were made when comparing mechanical performance of melatonin-treated control and HFD 
hearts when perfused under control conditions, before the onset of ischaemia. All parameters 
of mechanical function were similar as indicated in tables (3-3 A & B). The only difference 
was a reduction in aortic flow in control melatonin-treated hearts when compared to untreated 
controls. Hearts from melatonin-treated control and HFD rats showed the characteristic 
reduction in all parameters of function during reperfusion. However, no statistical difference 
was observed between any of the parameters in all four groups.  
Apart from the percentages recoveries in heart rate and coronary flow in hearts from the HFD 
group, no significant differences were observed in the percentage recoveries of the other 
parameters between the four groups, similar to the observations made when the absolute 
values were compared. 
 
Figure 3-9 Effect of diet and melatonin treatment on myocardial infarct size. 
** p<0.01 vs C and ### p<0.001 vs HFD, *p<0.05 C+M vs HFD+M (n=8/group) 
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Table 3-3 (A) Myocardial function before and after 35 min regional ischaemia 
Coronary flow (CF, ml/min), aortic output (AO, ml/min), cardiac output (CO, ml/min), systolic 
pressure (PSP, mmHg), heart rate (H/R, beats/min) and work total (WT, mWatts), *p<0.05, 
*** p<0.001 vs before; #p<0.05 vs control. 
 
Table 3-3 (B) Percentage (%) recovery of hearts subjected to regional ischaemia (R.I) 
Time Parameters C HFD C+M HFD+M 
Stabilization 
after 30 
minutes 
CF (ml/min) 16.56 ± 0.99 14.81 ± 1.08 12.38 ± 0.51 14.81 ± 1.34 
AO (ml/min) 42.75 ± 2.23 38.50 ± 2.20 38.00 ± 1.65 37.00 ± 2.54 
CO (ml/min) 59.31 ± 2.21 53.31 ± 2.70 50.38 ± 1.84# 51.81 ± 3.36 
PSP (mmHg) 96.50 ± 1.35 93.00 ± 0.95 91.25 ± 1.01 90.38 ± 0.91 
H/R (beats/min) 248 ± 8 247 ± 13.6 251 ± 10 279± 9.5 
  WT (mW) 12.58 ± 0.57 10.99 ± 0.56 10.23 ± 0.47# 10.43 ± 0.76 
Reperfusion 
after 30 
minutes 
CF (ml/min) 15.94 ± 1.39 8.25 ± 2.50 13.63 ± 0.91 10.81 ± 2.49 
AO (ml/min) 5.75 ± 1.62*** 7.00 ± 4.84*** 4.00 ± 1.60*** 4.50 ± 2.80*** 
CO (ml/min)  21.69 ± 2.84*** 15.25 ± 6.56*** 17.63 ± 2.32*** 15.31 ± 4.34*** 
PSP (mmHg) 82.38 ± 2.80*** 47.38 ± 15.35* 80.88 ± 2.00*** 61.38 ± 13.47* 
H/R (beats/min) 244 ± 8.8 164 ± 48 243± 9.7 205 ± 45 
  WT (mW) 4.07 ± 0.62*** 2.84 ± 1.33*** 3.22 ± 0.47*** 2.83 ± 0.83*** 
Time Parameters C HFD C+M HFD+M 
% recovery of 
hearts 
subjected to 
regional 
ischaemia 
CF (ml/min) 96.37 ± 5.673 55.82 ± 18.11 111.1 ± 7.95 82.98 ± 18.97 
AO (ml/min) 13.12 ± 3.934 15.49 ± 10.85 9.754 ± 3.883 12.31 ± 8.074 
CO (ml/min) 36.23 ± 4.348 26.40 ± 10.67 34.33 ± 3.653 31.70 ± 9.091 
PSP (mmHg) 85.25 ± 2.133 51.46 ± 16.61 88.57 ± 1.629 68.07 ± 14.91 
H/R (beats/min) 99.25 ± 5.422 66.35 ± 19.62 97.90 ± 4.687 75.07 ± 17.03 
  WT (mW) 31.69 ± 4.254 23.70 ± 10.28 30.74 ± 3.662 29.14 ± 8.720 
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Figure 3-10 Effect of diet and melatonin administration on (A) Cardiac output, (B) Aortic 
output, (C) Work total (i) before and (ii) after myocardial ischaemia 
(n=8/group),**p<0.05 vs C of the same parameter (aortic output), ***p<0.001 vs 
respective pre-ischaemic group (eg. Control before (i) vs Control after (ii)) 
 
C(i) 
(ii) B(i) 
(ii) A(i) 
(ii) 
 ** 
** 
*** 
*** 
*** 
*** 
*** 
*** *** *** 
*** 
*** *** *** 
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3.2.2 GLOBAL ISCHAEMIA 
 
To further evaluate the effect of the high fat diet and melatonin treatment on the functional 
performance of the isolated perfused rat heart as well as its response to ischaemia/reperfusion 
injury, hearts were subjected to a 40 minute stabilization period (pre-ischaemia), followed by 
20 minute global ischaemia and 30 minutes of reperfusion, during which time functional 
recovery was monitored. For the study of the signal transduction processes and Western 
blotting, a number of hearts were subjected to the same protocol, but freeze-clamped after 10 
min reperfusion only for maximal activation of the kinases. 
As was found in the previous study (Table 3-3), the high-fat diet had no significant effect on 
myocardial function during the control perfusion period before the onset of ischaemia: cardiac 
output (fig 3-11A), aortic output (fig 3-11B), total work (fig 3-11C), peak systolic pressure and 
heart rate, were similar in the control and HFD groups (Table 3-4 A & B). Exposure to 20 min 
global ischaemia, resulted in a significant reduction in aortic output, cardiac output and total 
work during reperfusion in both control and HFD groups. However, no difference between the 
response to ischaemia was observed. Melatonin treatment had no effect on the mechanical 
performance of control and HFD groups before as well as after ischaemia and no differences 
were observed between the four groups [fig 3-11 A(i), B(i) and C (i)]. However, a significant 
reduction in performance [fig 3-11 A(ii), B (ii)and C (ii)] during reperfusion was seen in all 
groups. Table 3-4 B shows the percentage recoveries of hearts during reperfusion after 
exposure to 20 min global ischaemia. As was the case in regional ischaemia, no significant 
differences were detected between hearts from control and HFD rats, while melatonin also did 
have a significant effect. 
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Table 3-4 (A) Myocardial function data: before and after 20 min global ischaemia 
Coronary flow (CF, ml/min), aortic output (AO, ml/min), cardiac output (CO, ml/min), systolic 
pressure (PSP, mmHg), heart rate (H/R, beats/min) and total work (TW, mWatts), *p<0.05, 
**p<0.005, ***p<0.0001 vs respective pre-ischaemic group. No significant changes were 
observed  in the same parameter  for the different groups (eg. C vs HFD for aortic output). 
 
 
Table 3-4 (B) Percentage (%) recovery of hearts subjected to global ischaemia (G.I) 
 
Coronary flow (CF, ml/min), aortic output (AO, ml/min), cardiac output (CO, ml/min), systolic 
pressure (PSP, mmHg), heart rate (H/R, beats/min) and total work (TW, mWatts). 
 
 
 
    
Time Parameters C HFD C+M HFD+M 
Stabilization 
after 40 
minutes of 
perfusion 
CF (ml/min) 15.38 ± 1.663 14.88 ± 1.59 13.13 ± 1.28 14.13 ± 1.33 
AO (ml/min) 47.5 ± 4.99 44 ± 4.69 41 ± 2.65 40.50 ± 1.5 
CO (ml/min) 62.88 ± 6.15 58.88 ± 5.93 54.13 ± 3.73 54.63 ± 2.34 
PSP (mmHg) 95 ± 2.12 96 ± 2.12 92.25 ± 2.02 90.75 ± 0.75 
H/R (b/min) 273 ± 21 258 ± 3.5 273 ± 9 257 ± 13 
TW (mW) 13.34 ± 1.58 12.62 ± 1.52 11.64 ± 1.36 11.01 ± 0.51 
Reperfusion 
after 30 
minutes 
CF (ml/min) 12.50 ± 0.84 12.25 ± 2.02 12.50 ± 1.54 9.75 ± 0.43 
AO (ml/min) 11 ± 4.34** 9.5 ± 6.19** 15.50 ± 5.12** 10.50 ± 2.36** 
CO (ml/min)  23.5 ± 4.73** 21.75 ± 7.79** 28 ± 6.15* 20.25 ± 2.24*** 
PSP (mmHg) 85 ± 1.683 82.25 ± 4.48 87.25 ± 2.29 85.75 ± 2.136 
H/R (b/min) 267 ± 25 248 ± 9.76 246 ± 6.59 224 ± 17.24 
TW (mW) 4.38 ± 1.05** 4.18 ± 1.69** 5.54 ± 1.30* 3.874 ± 0.49*** 
Time Parameters C HFD C+M HFD+M 
% recovery of 
hearts 
subjected to 
global 
ischaemia 
CF (ml/min) 82.71 ± 4.02 81.85 ± 7.198 94.90 ± 7.647 70.89 ± 7.061 
AO (ml/min) 21.09 ± 7.609 21.33 ± 12.89 36.83 ± 12.05 26.40 ± 6.169 
CO (ml/min) 36.41 ± 4.583 36.65 ± 11.29 50.98 ± 10.68 37.34 ± 4.544 
PSP (mmHg) 89.53 ± 1.558 85.58 ± 3.606 94.60 ± 1.840 94.53 ± 2.775 
H/R (beats/min) 97.66 ± 2.639 96.10 ± 3.333 90.12 ± 1.908 88.26 ± 9.058 
  WT (mW) 31.73 ± 4.992 32.50 ± 11.00 47.01 ± 10.76 35.47 ± 4.711 
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Figure 3-11 Effect of diet and melatonin administration on (A) Cardiac output, (B) 
Aortic output, (C) Work total (i) before and (ii) after myocardial ischaemia 
(n=4/group), *p<0.05, **p<0.005, ***p<0.0001 vs respective pre-ischaemic group. No 
significant changes were observed in the same parameter for the different groups (eg. C 
vs HFD for aortic output). 
 
 
Stellenbosch University  https://scholar.sun.ac.za
80 
 
3.3 EFFECT OF DIET AND CHRONIC MELATONIN TREATMENT ON 
INTRACELLULAR SIGNALLING 
 
As previously stated, the hearts that were freeze-clamped after 20 minutes of global ischaemia 
and 10 minutes of reperfusion were used for the evaluation of intracellular signalling. We 
investigated the effect of the diet and melatonin treatment on the following signalling 
pathways: the reperfusion injury salvage kinase (RISK) (PKB/Akt, ERK; baseline and 
reperfusion) and survivor activating factor enhancement (SAFE) (STAT3) pathways 
(reperfusion). Other kinases studied after 10 minutes reperfusion include: AMPK, JNK, UCP-
3 and PGC1-α. 
 
3.3.1 Reperfusion injury salvage kinases (RISK) pathway 
3.3.1.1 Baseline PKB/Akt and ERK 42/44  
The standard rat chow (control) and high-fat diet (HFD) had no significant effect on PKB/Akt. 
The HFD significantly increased ERK p44 expression and activation under baseline conditions 
while no effect on p42 was noted, compared to the controls. Melatonin treatment also had no 
effect on PKB/Akt or ERK 42/44 in both control and high-fat fed groups (figs 3-12 & 3-13, 
respectively). 
 
Figure 3-12 Baseline (non-perfused) phosphorylation of PKB/Akt (n=3/group)   
  C              HFD            C+M           HFD+M 
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Figure 3-13 Baseline phosphorylation of ERK 44/42, p44 *p<0.05 vs control, (n=4/group) 
 
 
3.3.2 PKB/Akt and ERK 44/42 following ischaemia/reperfusion   
Following 10 minutes of reperfusion, no differences in expression and activation of PKB/Akt 
were observed between the untreated and melatonin treated control and high-fat diet groups 
(fig 3-14). Similar observations were made for ERK 42/44 (fig 3-15). 
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Figure 3-14 PKB/Akt phosphorylation after 10 minutes of reperfusion (n=3/group)  
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Figure 3-15 ERK 42/44 phosphorylation after 10 minutes of reperfusion (n=3/group) 
 
 
3.3.3 Survivor activating factor enhancement (SAFE) pathway 
 
3.3.3.1 STAT3 phosphorylation (tyr 705) following 10 minutes of reperfusion 
The high-fat diet as well as chronic melatonin treatment did not affect the expression and 
phosphorylation patterns of both cytosolic and nuclear STAT3 (Tyrosine 705) after 10 min of 
reperfusion (figs 3-16 & 3-17).  
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Figure 3-16 Cytosolic STAT-3 phosphorylation (Tyrosine 705) after 10 minutes 
reperfusion (n=3/group) 
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Figure 3-17 Nuclear STAT-3 phosphorylation (Tyr 705) after 10 minutes reperfusion 
(n=3/group)  
 
3.3.3.2 STAT3 phosphorylation (ser 727) following 10 minutes of reperfusion 
Both the high-fat diet and treatment with melatonin had no effect on cytosolic STAT3 
expression and phosphorylation (Serine 727) after 10 minutes of reperfusion (figs 3-18). 
However, melatonin treatment of the HFD rats caused a reduction in the phosphorylation of  
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Figure 3-18 Cytosolic STAT-3 phosphorylation (Ser 727) after 10 minutes reperfusion 
(n=3/group) 
 
 
 
Figure 3-19 Nuclear STAT-3 phosphorylation (Ser 727) after 10 minutes reperfusion, 
#p<0.05 vs HFD, (n=4/group). 
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3.4 AMPK  following reperfusion  
The diet and melatonin treatment had no significant effect on the expression and 
phosphorylation of AMPK (fig 3-20) and JNK (fig 3-21) after 10 minutes of reperfusion. 
                       
 
Figure 3-20 AMPK phosphorylation after 10 minutes reperfusion (n=4/group) 
 
3.5  JNK following reperfusion 
 
 
Figure 3-21 JNK phosphorylation after 10 minutes reperfusion (n=3/group) 
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3.6  UCP3 following reperfusion 
The high-fat diet and melatonin treatment had no effect on UCP3 expression after 10 minutes 
of reperfusion (fig 3-22).  
                          
                        
Figure 3-22 UCP-3 expression after 10 minutes reperfusion (n=3/group) 
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3.7  PGC1-α following reperfusion 
 
The HFD as well as melatonin treatment had no effect on the expression of PGC-1α in the 
four groups studied.                                                                        
  
                                                                               
 
Figure 3-23 PGC1-α phosphorylation after 10 minutes reperfusion, (n=3/group) 
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CHAPTER 4  
 
 
DISCUSSION             
 
 
4.1 SUMMARY OF MOST SIGNIFICANT FINDINGS 
 
The purpose of the present study was twofold: (i) to characterize a new model of obesity, the 
so-called high fat diet (HFD), induced by a modification of the well-established sucrose diet of 
Pickavance et al. (1999) and its effects on the response of the myocardium to 
ischaemia/reperfusion injury and concomitant intracellular signaling (ii) the effects of chronic 
administration of melatonin in the drinking water on the above parameters in control and HFD-
induced obese rats. 
The most significant observations were that addition of cooking fat to the sucrose-containing 
diet of Pickavance et al. (1999) caused significant increases in body weight and visceral 
adiposity, associated with insulin resistance and the well-established changes in circulating 
leptin and adiponectin, while having no effect on the response of the heart to 
ischaemia/reperfusion damage, when compared with their age-matched control counterparts. 
Chronic consumption of melatonin had profound effects on body weight gain, insulin resistance 
as well as the myocardial response to ischaemia/reperfusion injury in both control and HFD 
rats. In contrast, the patterns of intracellular signaling, baseline as well as during reperfusion 
after ischaemia, showed no significant changes, except for baseline ERK p44 activation of the 
HFD goup which differed significantly compared to the controls (fig 3-13) and nuclear STAT-
3 phosphorylation (Ser 727) (fig 3-19). 
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4.2 THE EFFECTS OF HFD ON BIOMETRIC AND METABOLIC MARKERS 
 
 
It is common knowledge that obesity results from an imbalance between energy consumption 
and expenditure (Sikaris et al., 2004; for a review see Fernandez-Sanchez et al., 2011). It is 
also well-established that obesity induced by a HFD is a major contributor to the development 
of heart disease and diabetes (Birse et al., 2010).  
Our previous work on the sucrose diet-induced model of obesity (DIO) revealed that these 
animals are insulin resistant, but not diabetic (Nduhirabandi et al., 2014; Salie et al 2014). 
However the increases in body weight were rather modest and varied significantly. It was 
therefore decided to develop a new high fat diet by adding cooking fat to the sucrose-containing 
diet and to evaluate its effects on the biometric and metabolic parameters of rats after a 16 week 
feeding period. The data obtained in the present study showed that animals fed the HFD gained 
significantly more body weight (fig 3-1 A) and visceral fat (fig 3-1 B) with a higher adiposity 
index (Table 3-1) due to energy over-consumption compared to age-matched controls. These 
findings are consistent with previous studies from our laboratory, using the DIO diet (Du Toit 
et al., 2008; Nduhirabandi et al., 2011 & 2014; Salie et al., 2014) and other models of diet-
induced obesity (Puchalski et al., 2003; Hecker et al., 2012). However, the HFD over a period 
of 16 weeks appears to be more effective than the DIO diet in eliciting body weight gain over 
a period of 16 to 20 weeks (HFD, 30.5% (Table 3-1) vs ± DIO, 13% (Nduhirabandi et al., 2014; 
Salie et al., 2014) with little difference between the diets in visceral fat content gain.  
 
Significantly elevated blood glucose, plasma insulin and HOMA index values (fig 3-2 A, B 
and C, respectively) were observed in the high fat fed animals when compared to the controls. 
As was also observed in the DIO model, these rats were insulin resistant, but not diabetic: 
although Du Toit et al. (2008) as well as Nduhirabandi et al. (2011) reported unchanged blood 
glucose levels in the 16 week DIO model, elevated blood glucose levels were observed after 
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16 (Salie et al. 2014) and after 20 weeks on the DIO diet (Nduhirabandi et al. 2014), in 
agreement with the observations made in the present study. 
In addition to the observed increase in the HOMA index, the presence of insulin resistance 
induced by both DIO and HFD was confirmed by demonstration of a significant reduction in 
insulin-stimulated glucose uptake by cardiomyocytes isolated from these hearts (Huisamen et 
al., 2011; Flepisi et al., 2013; Nduhirabandi et al., submitted for publication).  
Although both DIO and HFD induced obesity were not associated with diabetes, it should be 
kept in mind that these animals were on their respective diets for 16 weeks only and the 
possibility exists that they may have developed type 2 diabetes should the period of HFD were 
prolonged. Insulin resistance is considered to be an important link between obesity and type 2 
diabetes (Kahn & Flier, 2000) with an increased risk for the development of cardiovascular 
disease (Wellen & Hotamisligil, 2005; Dunmore & Brown, 2013; Flehmig et al., 2014). 
However, thus far the question whether diet-induced obesity in experimental rats eventually 
leads to diabetes has not been addressed in the literature. 
 
Several reviews have suggested that increased adiposity leads to adipose tissue dysfunction 
and altered adipose tissue secretions or adipokine pathways (Bastard et al., 2006; for a review 
see Cao, 2014). Given that adipokines can act as markers or predictors of obesity-related 
diseases and that the roles of leptin and adiponectin in the setting of obesity are well- 
established, we investigated the levels of these adipokines in both control and HFD rats. Our 
results showed that plasma leptin concentrations were significantly higher in the HFD group 
(fig 3-3 A). Leptin serves as an adiposity signal with levels directly proportional to adipose 
tissue mass. High leptin levels are known to be associated with obesity, insulin and leptin 
resistance accompanied by impaired actions of leptin (Lin et al., 2000; Yingzhong et al., 2006).  
On the other hand, plasma adiponectin concentrations were significantly lower in the HFD 
group (fig 3-3 B), in accordance with the reported negative correlation between body mass 
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index and plasma adiponectin levels (Yamauchi et al 2003; Ouchi et al 2006). It is also 
generally accepted that adiponectin acts as a protective factor against the development of 
insulin resistance and diabetes (Ouchi et al 2006). Thus, these findings for leptin and 
adiponectin in the HFD model are in agreement with the DIO model as reported by 
Nduhirabandi et al. (2011 & 2014), respectively. Similar findings for leptin were observed in 
other HFD studies by Koch et al., (2014); and for adiponectin by Younan et al. (2013).  
 
 
4.2.1 HFD and oxidative stress  
 
The evidence for oxidative stress in the HFD model of obesity was reviewed by Matsuzawa-
Nagata et al. (2008); and has been associated with mitochondrial dysfunction (Bruce et al., 
2009). Furthermore, oxidative stress has been implicated in several obesity related pathologies 
with an increased cardiovascular risk (Grattagliano et al., 2008). 
The present study showed that the HFD elicited significant plasma lipid abnormalities as 
reflected by the higher plasma triglyceride (fig 3-4 B; Table 3-2), free fatty acid (fig 3-4 A; 
Table 3-2) and phospholipid levels (Table 3-2). Similar abnormalities were also seen in the 
DIO model (Du Toit, 2008; Nduhirabandi et al., 2014). However, no evidence of lipid 
peroxidation was observed since the TBARS and CD levels were unchanged by the HFD diet 
(Table 3-2), which is in agreement with findings by Nduhirabandi et al. (2011). While elevated 
TBARS levels were observed in rats receiving short-tem melatonin administration 
(Nduhirabandi et al. (2014). It therefore seems that both HFD and DIO diets administered for 
a period of 16 weeks are not associated with overt lipid peroxidation.  Although the DIO rats 
showed elevated TBARS levels (Nduhirabandi et al. (2014)), the differences disappeared when 
the data were normalized against total plasma triglyceride and phospholipid values. 
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4.2.2 High-fat diet, myocardial function and response to ischaemia/reperfusion damage 
 
The negative impact of obesity on myocardial function has been attributed to metabolic 
derangements such as insulin and leptin resistance, dyslipidemia and impaired glucose 
homeostasis resulting in ROS accumulation associated with mitochondrial dysfunction and 
oxidative stress (Chess & Stanley, 2008; Kim et al., 2008).  
Reports on the effects of obesity and insulin resistance on baseline myocardial function as well 
as I/R injury in experimental animals are controversial and subject to many confounding 
factors, for example the period of feeding, the age of the animals, the composition of the diet, 
to name but a few. In contrast to the reduction in baseline myocardial mechanical function 
reported in rats receiving the DIO diet for 16 weeks (Du Toit et al., 2008; Essop et al., 2009; 
Nduhirabandi et al., 2011), in the present study baseline function of hearts from rats fed a HFD 
did not differ from controls (Tables 3-3 & 3.4). Interestingly, du Toit and coworkers (Donner 
et al., 2013) could no longer detect any baseline contractile dysfunction when the period of the 
DIO diet was prolonged to 32 weeks. These workers also reported that a HFD (very similar in 
composition to ours) when given for 32 weeks had no deleterious effect on basal myocardial 
function whether evaluated either in vivo or in vitro (Wensley et al., 2013). 
Indications are that changes in myocardial metabolic patterns may underlie some of the 
discrepancies in baseline myocardial function. For example, the mechanical dysfunction 
reported in rats fed a Western diet with high fat and reduced carbohydrates (Wilson et al., 2007) 
was attributed to impaired fatty acid oxidation. Indeed, decreased long chain fatty acid 
oxidation during reperfusion has been shown to impair postischaemic recovery in hearts from 
rats on high sucrose diet (Harmancey et al., 2013). On the other hand, others have reported that 
hearts from obese insulin resistant mice showed well-preserved function when perfused with 
palmitate plus insulin (Mazumder et al., 2004; Buchanan et al., 2005). Our results, showing no 
difference between the baseline function of the control and obese groups, obtained with glucose 
Stellenbosch University  https://scholar.sun.ac.za
95 
 
as the only substrate ex vivo, were surprising in view of the plasma lipid abnormalities present 
in vivo in the diet group after 16 weeks (Tables 3-3,4), which may have predisposed hearts of 
obese rats toward fatty acid metabolism.   
 
Similarly, no differences in functional recovery during reperfusion (Tables 3-3 & 3.4) or infarct 
size (fig 3-9A) after exposure to 35 min regional ischaemia were observed between control and 
HFD groups. In addition, the HFD had no effect on functional parameters during reperfusion 
following 20 min global ischaemia and values obtained were similar to those of the controls 
(figs 3-11 A(ii), B(ii) and C (ii), Table 3-4). These results suggest that hearts from obese HFD 
animals are not more susceptible to ischaemic damage than their corresponding controls 
(Tables 3-3 & 3-4) which is in agreement with studies by Thim et al. (2006) and Salie and 
coworkers (2014).  
 
As mentioned above, the contribution of obesity and insulin resistance to I/R injury is complex 
and subject to many confounding factors (Miki et al., 2012; Whittington et al., 2012). 
Interpretation of the data is also complicated by reports of improved resistance to I/R in obesity 
(Donner et al., 2013; Salie et al., 2014). A reduction in infarct size was also observed in our 
laboratory after 16 weeks of a DIO diet (Huisamen and Fan, unpublished data). The above 
observations are in contrast with the results obtained by Du Toit and coworkers (2008) in 16 
weeks fed DIO rats namely a significant increase in infarct size accompanied by a reduction in 
functional recovery during reperfusion after 35 min regional ischaemia. As yet, we do not have 
an explanation for these contradictory observations, but may be due to the different diet 
compositions. The lack of protection previously reported by Salie et al (2014) may be due to 
the difference in sample size (n=8 in the present study while Salie et al (2014) used n=5).   
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Despite evidence for a higher prevalence of obesity in patients with myocardial ischaemia, a 
number of recent publications suggested that obesity in humans with ischaemic heart disease 
is associated with reduced morbidity and mortality, the so-called “obesity paradox” (Chase et 
al., 2014; Clark et al., 2014). Our experimental results as well as those of others could indicate 
that this may also be true for obese animals. Unfortunately the mechanisms involved are 
unclear at this point in time. 
 
4.3 Intracellular signaling 
Expression of myocardial total and phosphorylated kinases was evaluated in baseline 
conditions as well as at 10 min reperfusion after 20min global ischaemia. The reason for 
choosing the latter model of ischaemia (rather than regional ischaemia) is that it yields a 
relatively large amount of tissue, while circumventing the problem of contaminating ischaemic 
tissue with normal tissue as may occur in regional ischaemia.  
Similar baseline total and phosphorylated ERK p44/p42  and PKB were observed in hearts 
from control, HFD (Salie et al., 2014) and DIO (Nduhirabandi et al., 2014) rats, while 
unchanged total and phosphorylated STAT3 in both nuclear and cytosolic fractions were 
reported in DIO rat hearts when compared to the controls (Nduhirabandi et al., 2014). In the 
present study, similar observations were made: no changes in baseline total and phosphorylated 
PKB and ERK p42 were observed, however, phosphorylation of ERK p44 was seen in HFD 
rat hearts after 16 weeks on the diet (figs 3-12, 13). Interestingly, Wensley and coworkers 
(2013) found that feeding of a high fat obesogenic diet for 32 weeks resulted in a marked 
reduction in the activity of the RISK pathway. These observations suggest that the feeding 
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period may affect intracellular signaling pathways. However this possibility remains to be 
further investigated. 
A number of differences in intracellular signaling emerged when activation of the RISK 
pathway was evaluated in hearts from control, DIO (Nduhirabandi et al., 2014) and HFD (Salie 
et al., 2014) rats after exposure to 20 min global ischaemia followed by 10 min of reperfusion. 
Nduhirabandi et al. (2011, 2014) could not detect any significant differences in ERK p44/p42 
and PKB as well as GSK3β activation between control and DIO hearts during reperfusion. 
Although Salie et al (2014) found that the activation patterns of ERK p44/p42 and PKB were 
similar in control and DIO hearts, significantly less activation of both kinases occurred in hearts 
from the HFD rats. However, in the present study the expression and phosphorylation of ERK 
p44/p42, PKB and STAT3 during reperfusion after global ischaemia were similar in the HFD 
and control groups. Unfortunately Wensley and coworkers (2013) did not evaluate the RISK 
pathway during reperfusion of hearts from rats fed an obesogenic diet for 32 weeks. It is clear 
that the effects of diet composition on intracellular signaling need to be further investigated.  
 
4.4 UCP3 and PGC-1α 
In this study we also evaluated the respective roles of the uncoupling protein UCP3 and PGC-
1-α in hearts from control and HFD rats. The uncoupling protein family has been reported to 
play an important regulatory role in mitochondrial function and free radical (ROS) generation 
(Mailloux & Harper, 2011). However, not much is known about these proteins in 
cardiovascular disease and results obtained are controversial (Akhmedov et al., 2015). In 
cardiomyocytes the mitochondria are a major source of reactive oxygen species. It is known 
that elevated ROS levels, as occurs during reperfusion, stimulate proton leaks mediated by 
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UCP3, leading subsequently to attenuation of ROS generation. The first evidence for a role for 
UCP3 in cardioprotection in experimental I/R was published recently (Ozcan et al., 2013) using 
knockout (UCP-/-) mice to demonstrate that ischaemic preconditioning was abolished in such 
mice. UCP2 and UCP3 have been shown to confer protection against ischaemia-reperfusion 
injury by others, but their role in the heart is yet to be established (Sack, 2006; Bodyak et al., 
2007). UCP3 is closely associated with fatty acid metabolism, as its expression is 
downregulated when fatty acid oxidation is improved (Russell et al., 2003) and conversely, its 
levels are upregulated when the fatty acid supply exceeds oxidation as occurs upon a HFD 
(Weigle et al., 1998).  
UCP3 has been shown to be reduced by 50% in skeletal muscle of obese type 2 diabetic patients 
(Krook  et al., 1998; Schrauwen  et al., 2001), while its expression is markedly increased in 
cardiac tissue of human heart failure patients (Murray  et al., 2004). It has also recently been 
shown that UCP3 might affect cardiac energy efficiency under high fat conditions (Boudina et 
al., 2012). However, in the present study no significant differences in UCP3 expression were 
detected between hearts from control and HFD rats (fig 3-22).  It should be kept in mind that 
these analyses were done at 10 min reperfusion and it is possible that different results could 
have been obtained if samples were taken at baseline. The role of UCP3 in HFD-induced 
obesity should be further investigated.  
Peroxisome proliferator-activated receptor γ coactivator -1α (PCG-1α) is an inducible 
integrator of transcriptional circuits that regulate mitochondrial biogenesis and function. In the 
heart PGC1-α regulates the expression of genes encoding oxidative phosphorylation subunits 
and FFA metabolism proteins (Huss et al., 2004; Lehman et al., 2000). Thus this protein plays 
a central role in the regulation of fuel selection and mitochondrial ATP generating capacity and 
energy production in the heart.  A recent study showed that hypoadiponectonemia, as is present 
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in obesity, impairs AMPK-PGC1α signaling resulting in dysfunctional mitochondrial 
biogenesis in neonatal rat ventricular myocytes (Yan et al., 2013). Thus the possibility exists 
that its expression and function may be altered in the presence of high circulating FFA 
concentrations and reduced plasma adiponectin levels as are present in rats fed a HFD for a 
period of 16 weeks. The preliminary data obtained in this study indicated that PGC1-alpha 
expression in hearts from HFD rats was similar to that of control hearts (fig 3-23). However, 
PGC1-α activation is modulated amongst others by acetylation at multiple acetylation sites 
which can occur via SIRT1 (Yan et al 2013). Thus evaluation of PGC1-α acetylation still needs 
to be done to allow more complete evaluation of this system in hearts from HFD rats. 
 
4.5 EFFECT OF MELATONIN ON HFD-INDUCED OBESITY 
 
There is increasing evidence for the use of antioxidants in treating obesity and its related 
pathologies, including cardiovascular disease (Ramos-Marquez et al., 2008). The potent free 
radical scavenging and anti-oxidant properties of melatonin have been discussed in detail in 
Chapter 1. In the present study we investigated the effects of melatonin on HFD-induced 
obesity and the heart.  Melatonin was given at an oral dosage of 10mg/kg/day, which is higher 
than in our previous studies (4mg/kg/day, see Nduhirabandi 2011, 2014), but in agreement with 
several other studies in this regard (Shieh et al., 2009; Kitagawa et al., 2012). 
 
Daily rhythms have been well implicated in metabolic homeostasis and disruption thereof has 
been associated with pathologies such as diabetes (Antunes et al., 2010; Kennaway et al., 
2011), cancer and cardiovascular disease (for a review see Dominguez-Rodriguez et al., 2010).  
The pineal gland hormone, melatonin, is tightly controlled by the circadian clock and is 
released in a rhythmic fashion in blood (Reiter et al., 1991; for a review see Dominguez-
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Rodriguez et al., 2010). Due to its circadian rhythmic secretion, melatonin is known to act as 
an ‘internal synchronizer’ with implications for timing of central (hypothalamus) and 
peripheral tissue (adipose tissue, skeletal muscle) functions thus mediating metabolic cycles 
necessary to maintain energy homeostasis, amongst many others (for a review see Cipolla-Neto 
et al., 2014). 
 
Melatonin’s involvement in metabolic regulation and weight-loss has been well studied (see 
Rasmussen et al., 1999; Wolden-Hanson et al., 2000; Prunet-Marcassus et al., 2003; Hussein 
et al., 2007; Rios-Lugo et al., 2010 and Nduhirabandi et al., 2011 & 2014). In a carefully 
controlled study Nduhirabandi showed that the daily consumption of melatonin had no effect 
on the food intake of both control and HFD rats (Nduhirabandi et al., 2014) and that this factor 
was thus not responsible for the characteristic weight loss. Also in the present study the 
presence of melatonin in the drinking water had no effect on the food intake in both the control 
and HFD groups. However, other studies did show a reduction in food intake (at 1 mg/kg 
Hussein et al., 2007; 20µg/ml Sanchez-Mateos et al., 2007), suggesting that melatonin’s effects 
may perhaps depend on the type of diet, dosage and duration of administration. 
Following the 16 week diet (standard rat chow or high-fat) and daily melatonin treatment (10 
mg/kg/day) regime, our study revealed that the intake of melatonin prevented body weight gain 
in both control and HFD animals (fig 3-5A) compared to their untreated counterparts. In 
addition, the enlarged visceral fat mass due to the HFD was also significantly reduced with 
chronic melatonin consumption as seen in fig 3-5B. The oral intake of melatonin associated 
with body weight reduction was also evidenced in the DIO model (Nduhirabandi et al., 2011) 
and in studies by Wolden-Hanson et al. (2000) on rats receiving a normal laboratory rodent 
diet and Prunet-Marcassus et al. (2003) using rats on a high fat diet. The melatonin dosage does 
not appear to be important since a reduction in body weight was reported by using different 
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dosages of melatonin Rasmussen et al. (1999) (30-40 µg/kg), Wolden-Hanson et al. (2000) 
(14-35 µg/kg) and Nduhirabandi et al. (2011) (4-6 mg/kg/day).  
 
The link between the pineal gland and body weight regulation was nicely demonstrated in a 
study employing pinealectomized rats, where the  reduction in circulating levels of melatonin 
was associated with increased body weight gain (Prunet-Marcassus et al., 2003). Upon 
melatonin supplementation (30mg/kg/day for 3 weeks), the body weight gain was reduced in 
these rats (Prunet-Marcassus et al., 2003) confirming a role for endogenous melatonin in body 
weight regulation. 
 
Although the anti-obesogenic effects of melatonin are not fully understood, it may act via its 
effects on brown adipose tissue.  It is well-known that brown adipose tissue (BAT) functions 
to dissipate energy via heat production (Gesta et al., 2007; Zhou et al., 2014) and melatonin 
has been implicated in activation of brown adipose tissue and browning of white adipose tissue 
(Heldmaier et al., 1974; for a review see Cipolla-Neto et al., 2014), suggesting a thermogenic 
aspect whereby melatonin may induce weight loss (Jimenez-Aranda et al., 2013).  
 
Melatonin is known to exert most of its actions via activation of membrane or nuclear receptors 
(Rodriguez et al., 2004; Wiesenberg 1998). In this regard, it has been proposed that it affects 
adipose tissue mass via the MT1/MT2 receptors present in adipose tissue, by sympathetic 
nervous system activation (Bartness et al., 2002) and activation of the uncoupling protein 
(UCP1) present in brown adipose tissue (for a review see Navarro-Alarcon et al., 2014).  
Determination of the effect of melatonin on adipose tissue UCP1 should give more insight into 
its effects on body weight regulation. In non-obese rats, the body weight reduction could be 
linked to the anti-ageing properties of the melatonin, maintaining the metabolic/physiologic 
parameters at youthful levels (Rasmussen et al., 1999; Wolden-Hanson et al., 2000). 
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4.5.1 Interplay between melatonin, leptin and insulin on body metabolism 
 
Under physiological conditions, leptin (secreted by adipose tissue) and pancreatic insulin act 
in the hypothalamic centers as adiposity signals to relay information about peripheral fat stores 
and consequently control energy metabolism (Spanswick et al., 1997 & 2000; Alonso-Vale et 
al., 2005). 
Several reports have highlighted a close relationship between melatonin and its capacity to 
influence insulin secretion as its MT1 and MT2 receptors are expressed in pancreatic islets 
(Peschke et al., 2013) suggesting that melatonin may play a role in the control of insulin 
production (Mulder et al., 2009). The relationship between melatonin and leptin is less well 
defined, however, it is known that both hormones display a circadian rhythm with peak values 
at night (Alonso-Vale et al., 2005) and since melatonin, via its receptors, act directly on 
adipocytes, it can possibly modulate leptin levels in this manner (Brydon et al., 2001).  
 
Results from the present study show that melatonin significantly reduced plasma leptin levels 
(fig 3-7A) in the HFD animals compared to their untreated counterparts indicating that 
melatonin supplementation should have a significant effect on leptin signaling, regulation of 
body weight and metabolic processes in obesity. Similar observations were made in a HFD 
study by Rios-Lugo et al. (2010). In the present study melatonin significantly lowered plasma 
insulin levels, (fig 3-6 B) which is in agreement with other models of high-fat diet-induced 
obesity (Puchalski et al.2003; Hussein et al., 2007; Nduhirabandi et al., 2011 & 2014), control 
rats (Wolden-Hanson et al 2003)  and in a type 2-diabetic model using Goto-Kakizaki rats 
(Peschke et al., 2010). 
 
Interestingly, we found that treatment with exogenous melatonin counteracted the raised blood 
glucose levels (fig 3-6 A) caused by the HFD. Similar blood glucose lowering effects by 
melatonin were observed in studies using melatonin at 30 (Prunet-Marcassus et al., 2003), 1 
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(Hussein et al., 2007), 2.5, 5, 10 and 20 (Bibak et al., 2014) and 10 mg/kg/day (She et al., 2009; 
Bibak et al., 2014).  Contrary to these findings, the blood glucose levels were not reduced in 
the DIO with melatonin administration at 4mg/kg/day (Nduhirabandi et al. 2011 & 2014). 
 
Contrasting data exist for the effect of melatonin on glucose homeostasis in healthy animals 
possibly due to the absence of metabolic disorders, although studies suggest that it may increase 
glucose tolerance and insulin secretion in such animals (La Fleur et al., 2001) while improving 
insulin sensitivity and thus glucose uptake in obese and middle-aged rats (Larkin et al., 2001). 
 
A role for melatonin receptors has also been implicated in this regard. Reports have shown that 
removal of the MT1 receptor resulted in impaired glucose metabolism and insulin resistance 
confirming that melatonin is associated with blood glucose regulation (Contreras-Alcantara et 
al., 2010). Sartori & coworkers (2009) further showed that glucose homeostasis was improved 
in insulin resistant rats when treated with melatonin. Furthermore, a reduction in melatonin 
levels (due to aging/night shift work leads to insulin resistance associated with 
chronodisruption and metabolic abnormalities as seen in obesity (for a review see Cipolla-Neto 
et al., 2014). Given that treatment with melatonin has marked beneficial effects on body weight 
regulation and metabolism (amongst others), it is suggested that melatonin treatment may re-
establish timing of metabolic processes and reduce the aforementioned pathologies associated 
with obesity (for a review see Cipolla-Neto et al., 2014). 
 
Finally, it has to be kept in mind that in most experimental studies on the effects of melatonin 
in experimental animals, melatonin is continuously present in the drinking water and may cause 
elevated circulating melatonin levels throughout the day, which is in contrast with the cyclic 
changes present in vivo. However, circulating melatonin levels have not been determined in 
the present study. Previous studies have shown that melatonin is more effective when given 
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shortly before dark (lights out) and that rats consumed more than 80% of their water intake 
during the dark (Wolden-Hanson et al., 2000; Prunet-Marcassus et al .,2003).  It has also been 
shown, that using such an administration protocol, caused significant elevations in circulating 
melatonin levels during the night, while daytime levels were similar to those of untreated 
controls (Wolden-Hanson et al., 2000).  In the present study melatonin was always given 
shortly before dark as suggested by Wolden-Hanson and coworkers (2000). It should also be 
taken into account that time of blood collection during melatonin treatment could affect plasma 
levels of insulin, glucose, adiponectin, cholesterol etc (Rios-Lugo et al., 2010).  In the present 
study blood samples were collected early in the morning (~9h00). 
 
4.5.2 Effect of melatonin on adiponectin  
 
Diet-induced obesity is known to be associated with low circulating levels of adiponectin as 
evidenced in this study as well as other studies on obesity by Arita et al. (1999) and 
Nduhirabandi et al. (2014). Nduhirabandi and coworkers (2014) reported a significant increase 
in plasma adiponectin levels after melatonin treatment in the DIO animals. The association 
between melatonin administration and increases in plasma adiponectin levels was also 
demonstrated in streptozotocin-induced diabetes (de Oliveira et al., 2012) and in high fructose-
induced metabolic syndrome in rats (Kitagawa et al., 2012). Interestingly, melatonin treatment 
of patients with non-alcoholic steatohepatitis, reversed the reduction in plasma adiponectin 
levels observed in these patients (Gonciarz et al., 2013). However, melatonin treatment in our 
study was not associated with increased adiponectin levels in either the control or HFD rats as 
shown in fig 3-7 B. The reason for this discrepancy is not clear: the dosage as well as period 
of melatonin treatment was sufficient to elicit changes in several parameters studied, so one 
has to assume that the high fat diet through a hitherto unknown mechanism, prevented the 
effects of melatonin on plasma adiponectin. 
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4.6 EFFECT OF MELATONIN ON THE LIPID PROFILE            
 
The impact of obesity on lipid metabolism has been widely reviewed. Obesity is frequently 
associated with high plasma triglyceride and free fatty acid (FFA) levels (Dresner et al., 1999) 
which can stimulate insulin secretion. However prolonged exposure to these lipids result in 
impaired β-cell function associated with an insulin resistant state (Kashyap et al., 2003). In 
fact, it has been stated that the cornerstone affecting insulin insensitivity is the release of FFA. 
Increased release of FFA is observed in type 2 diabetes and in obesity and is associated with 
insulin resistance in both conditions (Kahn et al., 2006). Hyperlipidemia is also considered as 
a component of the metabolic syndrome or of a clustering of metabolic pathologies associated 
with increased cardiovascular and type 2 diabetes risk (Reaven, 2004).  
Despite these marked lipid abnormalities in HFD rats, plasma analysis with regard to TBARS 
and conjugated dienes (CD) showed no evidence of lipid peroxidation caused by the diet (Table 
3-2), which could explain why treatment with melatonin had no significant effect in this regard. 
On the other hand, Nduhirabandi et al. (2011 vs 2014) showed that the DIO model also did not 
affect TBARS and CD levels, while treatment with melatonin (4 mg/kg/day for 16 weeks) 
reduced the absolute TBARS levels. She et al 2009 using a rat model of high-fat/high sucrose 
diet-induced obesity, also showed that treatment with melatonin (4 mg/kg/day for 8 weeks) 
reduced oxidative stress as evidenced by lower malondialdehyde and increased superoxide 
dismutase levels. Melatonin-induced improved antioxidant status has also been reported in 
obese animals by She et al. (2009) and in studies on obese humans (Kozirog et al. 2011), 
possibly due to the hormone’s powerful antioxidant properties (Bonnefont-Rousselot & Collin, 
2010). 
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4.7 MELATONIN AND MYOCARDIAL ISCHAEMIA-REPERFUSION INJURY 
 
4.7.1 Obesity and ischaemia-reperfusion injury 
 
It is well-known that obesity and insulin resistance are considered as major risk factors for 
ischaemic heart disease (Jokinen, 2014) and may increase the susceptibility of the myocardium 
to ischaemia-reperfusion injury (Du Toit et al., 2008), increasing the risk for acute myocardial 
infarction (Kannel et al., 1965).  
Despite the fact that numerous reports highlighted the increased incidence of ischaemic heart 
disease in obese individuals, a growing number of studies have described the opposite, namely 
a reduced morbidity and mortality in obese individuals, the so-called ‘obesity paradox’ (Chase 
et al., 2014; Clark et al., 2014). The injurious effects of ischaemia-reperfusion on the heart 
have been studied for decades both in vivo and ex vivo. It is characterized by, amongst others, 
cardiac contractile dysfunction, arrhythmias, irreversible myocyte damage and cell death (for 
a review see Opie et al., 2004).  
It is well-documented that the damage encountered in the ischaemic-reperfused heart occurs 
partially as a result of hypoxia during a prolonged ischaemic insult. Although reperfusion is 
essential for recovery of damaged cells, it also has marked deleterious effects, the so-called 
reperfusion-injury. Reperfusion is associated with pH normalization, accumulation of free 
radicals (reactive oxygen/nitrogen species) and intracellular calcium (Maxwell et al., 1997; 
Bolli & Marban, 1999)  followed by opening of the mitochondrial permeability transition pore 
(MPTP) (Hausenloy et al., 2009; for a review see Perrelli et al., 2011), which may lead to the 
death of some damaged cells.  
Considering the facts that melatonin is associated with weight loss and improved metabolic 
abnormalities related to obesity, thus reducing the risk for cardiovascular disease, we 
investigated the effects of chronic administration of the hormone on the outcome of myocardial 
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ischaemia-reperfusion of hearts from healthy and obese animals (perfused in the absence of 
exogenous melatonin).  
 
 
4.7.2 Effect of diet and melatonin treatment on myocardial infarct size and functional 
recovery 
 
Amongst its many remarkable properties, melatonin, whether acutely or chronically 
administrated at supraphysiological concentrations, has been reported to have protective effects 
against the damage caused by ischaemia-reperfusion (for reviews see Reiter & Tan, 2003; 
Tengattini et al., 2008; Lochner et al., 2013). 
In the present study, the effect of chronic melatonin administration (16 weeks) on myocardial 
functional parameters before 35 min coronary artery ligation (ie baseline) showed a significant 
though small effect on the cardiac output of the treated control animals (fig 3-10B i, Table 3-
3). As for the functional parameters during reperfusion after 35 min coronary artery ligation, 
no significant differences were observed between the four groups. Thus melatonin treatment 
did not have a beneficial effect on the functional recovery of control or obese rat hearts, despite 
the significant reduction in infarct size. Similarly, functional recovery during reperfusion after 
20 min global ischaemia, did not differ significantly between the groups regardless of 
melatonin pretreatment (figs 3-11, Table 3-4). 
This dissociation between a reduction in infarct size and an improvement in functional recovery 
confirms previous observations made by Schulz et al. (2001), Lochner et al. (2003) and Genade 
et al. (2008) and is attributed to myocardial stunning during reperfusion (Lochner et al., 2003), 
which possibly over-rides the effects of melatonin on tissue damage (necrosis). However, in 
the DIO studies by Nduhirabandi et al. (2011 & 2014), melatonin was associated with both 
increased functional recovery as well as a reduction in infarct size of hearts from obese rats. 
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This could be attributed to the ability of melatonin to improve calcium homeostasis and /or its 
free radical scavenging properties (Salie et al., 2001).  
 
Despite the lack of effect on functional recovery, chronic treatment with melatonin for 16 
weeks reduces myocardial susceptibility to I/R damage in both control and HFD rats as 
evidenced by the reduction in infarct size in both groups. Measurement of infarct size is widely 
accepted as a more reliable indicator of tissue damage than functional recovery during 
reperfusion and is generally accepted to be the “golden standard” in the assessment of tissue 
damage (Genade et al., 2008).  
As noted in previous studies, these hearts were perfused in the absence of exogenous melatonin 
and it must be concluded that chronic melatonin administration caused changes in the heart 
which persist upon removal and which are still present during the perfusion protocol. Previous 
studies have also shown that these cardioprotective effects persist for at least 4 days after 
withdrawal of melatonin (Lochner et al., 2006). We have also shown that these long-term 
protective effects are melatonin receptor dependent, since pretreatment of these animals with 
luzindole (a melatonin receptor blocker) abolished the beneficial effects (Lochner & Genade, 
unpublished data). 
Besides the long–term effects, acute administration of melatonin to the perfusate of perfused 
rat hearts also demonstrated the cardioprotective effects of melatonin against I/R injury (Reiter 
& Tan 2003; Tengattini et al., 2008, Lamont et al., 2011; Lochner et al., 2013). As expected, 
Sahna et al. (2002) demonstrated that myocardial infarct size was significantly greater in 
untreated pinealectomized rats than those treated with melatonin.  
 
The exact mechanism through which melatonin confers its cardioprotective effects is not 
known, although convincing evidence suggest that melatonin’s effect in this regard can be 
attributed to its powerful antioxidant and free radical scavenging properties (Sahna et al., 2002; 
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Reiter  & Tan, 2003; Genade et al., 2008; Tengattini et al., 2008). Acute melatonin 
administration was shown to protect the isolated ischaemic heart via its anti-adrenergic actions 
(via nitric oxide (NO)) with guanylyl cyclase and protein kinase C (PKC)) as important role 
players (Genade et al., 2008; Lochner et al., 2013). The melatonin receptors are also involved 
in these actions since the use of a melatonin receptor antagonist, luzindole, blocked the 
cardioprotective effects of the hormone (Lochner et al 2006).  
 
 
4.8 MELATONIN AND CARDIOPROTECTION: INVOLVEMENT OF THE RISK 
AND SAFE PATHWAYS  
 
Very little is known about events downstream of melatonin receptor stimulation after chronic 
treatment with the hormone. It was therefore decided to study of role of the RISK (Reperfusion 
Injury Salvage Kinase) pathway which entails investigation of the expression as well as 
activation of protein kinase B (PKB/Akt) and extracellular signal-regulated kinase 
(ERKp44/p42) in isolated hearts under baseline conditions (non-perfused) as well as during 
reperfusion after exposure to ischaemia.  
We found that the expression of phosphorylated and total PKB/Akt and ERK p44/p42 as well 
as the phosphorylated/total ratios (fig 3-12,13) of both kinases under baseline conditions were 
unaffected by the 16 week HFD and melatonin treatment. Similar observations were made by 
Nduhirabandi et al in DIO treated hearts (2011).   
Although there were exceptions, many studies have shown an association between activation 
of these pro-survival kinases and cardioprotection during reperfusion (Hausenloy & Yellon, 
2007). In view of this, we sought to investigate the protein changes following 20 minutes of 
global ischaemia and 10 minutes reperfusion in hearts from these treated and untreated control 
and HFD animals.  
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The results showed that the HFD as well as melatonin treatment had no significant effect on 
the expression and activation of PKB/Akt (fig 3-14) and ERKp44/p42 (fig 3-15) during 
reperfusion when compared with the control hearts. This was a surprising finding, particularly 
in view of the marked reduction seen in infarct size of both groups (see fig 3-9B) but consistent 
in functional recovery after global ischaemia (fig 3-11). Several studies have shown that 
melatonin-induced cardioprotection is associated with PKB/Akt and ERKP44/P42 activation 
during early reperfusion. For example, Genade et al. (2008) showed that melatonin (50 µM) 
significantly activated the RISK pathway in non-obese animals, while reducing p38MAPK 
activation. Similar observations were also made by Lamont et al. (2011) using much lower 
concentrations of melatonin (75 ng/L). Using the DIO model of obesity, Nduhirabandi and 
coworkers (2011, 2014) confirmed the activation of both PKB/Akt and ERK p44/p42 as well 
as GSK-3β during reperfusion induced by short-term melatonin treatment. It is possible that 
the diet, the composition thereof as well as the period of treatment and dosage could affect the 
outcome of melatonin treatment on the RISK pathway. 
 
It has been reported that under baseline conditions and after reperfusion, melatonin also has a 
significant effect on STAT3 phosphorylation (Nduhirabandi et al., 2014): it was shown that 
melatonin treatment was associated with increased phosphorylation of cytosolic (Tyr 705) as 
well nuclear STAT3 (Tyr 705) in both control and DIO groups after 10 minutes reperfusion. 
Melatonin-induced activation of STAT3 by low circulating concentrations has also been 
reported by Lamont et al. (2011) before ischaemia/reperfusion. However, such changes were 
not seen in the control and HFD treated hearts in the present study (figs 3-16 to 3-18) after 
reperfusion, except for nuclear STAT3 (Ser 727), where melatonin had a significant effect on 
the HFD group (fig 3-19). 
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Thus it is clear from the results obtained in the present study, that the very significant reduction 
in infarct size induced by melatonin in control and particularly the HFD group, is not 
necessarily associated with activation of RISK and SAFE signaling pathways. Although there 
is a wealth of experimental evidence supporting the causal role of these pathways in 
cardioprotection, there are also a number of studies where this association could not be 
demonstrated (see editorial by Heusch, 2009) raising the question whether RISK activation is 
truly mandatory for cardioprotection. More insight into the mechanisms should be obtained by 
using appropriate knockout models or pharmacological approaches. A possible contributing 
factor to the absence of activation of the RISK and SAFE pathways may be the small sample 
size – in most studies only three hearts were studied. A shorter perfusion period should also be 
considered, although previous studies in our laboratory showed that maximal activation of both 
pathways are usually seen at this time point (10 min), while n values of 3 are usually sufficient 
in the case of Western blotting (Lochner & Salie, unpublished observations). 
 
The absence of activation of the RISK and SAFE pathways by melatonin in the present study 
now raises the question about the exact mechanism whereby melatonin exerts its 
cardioprotective effects which were particularly evident in the HFD group. Links have been 
proposed between the RISK and SAFE pathways and the mitochondrial permeability transition 
pore as final effector of cardioprotection. It has been suggested that these pathways are not 
mutually exclusive but potentially cooperative, converging on the mitochondrial permeability 
transition pore and inhibiting opening thereof (Boengler et al., 2010; Heusch et al., 2010). 
Indeed Petrosillo and coworkers (2009) presented convincing evidence that melatonin induced 
inhibition of the mitochondrial permeability transition pore, resulting in cardioprotection in 
control rats. The contribution of this pore to melatonin-induced cardioprotection in obesity 
remains to be determined. 
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4.8.1 AMPK 
 
It is well-established that adenosine monophosphate-activated protein kinase (AMPK) is 
involved in cellular energy metabolism and activated by the increase in tissue AMP/ATP ratio 
(Gowans et al., 2013) as occurs in conditions of oxidative stress (Auciello et al., 2014). Given 
the fact that melatonin is associated with body weight regulation and energy metabolism (for a 
review see Cipolla-Neto et al., 2014), we investigated the effect of melatonin on post-ischaemic 
AMPK. Our results showed no effect of melatonin on AMPK expression or activation 
following 10 minutes reperfusion (fig 3-20), consistent with findings by Nduhirabandi et al. 
(2011). Interestingly, melatonin treatment also had no effect on AMPK activation in skeletal 
muscle both in vivo and in vitro (Teodoro et al 2014), while not affecting AMPK in HepG2 
cells (Shieh et al 2009).  It was concluded that it is very unlikely that melatonin confers 
cardioprotection via activation of AMPK during  reperfusion. 
 
 
4.8.2 c-Jun N-terminal kinase (JNK) 
 
ERK, p38MAPK (not assessed in this study) and c-Jun N-terminal kinase (JNK) belong to the 
family of mitogen-activated protein kinases (MAPKs) that are involved in regulation of 
apoptosis in cardiomyocytes (Rose et al., 2010) and inflammation (Kyriakis et al., 1996).  It 
has recently been suggested that activation of the stress kinase JNK is essential for PKB 
phosphorylation at the onset of reperfusion (Shao et al., 2006): activation of JNK 
phosphorylates PKB on Thr450, demonstrated to be a prerequisite for the phosphorylation of 
PKB at Thr308 and Ser473 to be fully active. Thus, these observations suggest that JNK 
activation during early reperfusion could be a prerequisite for cardioprotection. 
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However, despite the above convincing data (Muniyappa et al., 2007; Shao et al., 2006; Sato 
et al., 2000), the role of JNK activation in cell survival is not at all clear. For example, it has 
been reported that pharmacological inhibition of JNK activation during early reperfusion is 
cardioprotective, indicating that this kinase is pro-apoptotic (Ferrandi et al., 2004). JNK has 
been shown to phosphorylate the 14-3-3 scaffolding proteins, thereby releasing BAX to 
translocate to the mitochondria where it mediates release of cytochrome C and activates 
apoptosis (Dhanasekaran et al., 2008). However, this kinase is surprisingly under-researched 
in the phenomenon of ischaemia/reperfusion, particularly in the case of insulin resistant hearts. 
From our results no significant JNK activation in the presence of melatonin in both control and 
HFD groups (fig 3-21) was observed after a reperfusion period of 10 min, suggesting that this 
kinase is probably not involved in the cardioprotective actions of melatonin, although ideally 
sampling should have been done at an earlier reperfusion time-point. 
 
4.8.3 UCP-3 and PGC1-α 
 
In view of the increased circulating FFA concentrations in HFD rats, changes in myocardial 
UCP3 were expected. However, no difference was observed between the expression of UCP3 
in the control and HFD untreated hearts; melatonin also had no effect on the expression of this 
protein (fig 3-22). 
 
In the interpretation of these results, it should be borne in mind that these hearts were subjected 
to ischaemia and freeze-clamped during reperfusion in the absence of melatonin. It is possible 
that more marked effects would have been observed in the presence of melatonin in the 
perfusate. It is also possible that changes in UCP3 expression occurs at times other than 10 min 
reperfusion, for example during baseline conditions.  
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Melatonin’s lipophilic properties allow it to act in cellular and subcellular compartments (Vural 
et al., 2001) and to maintain mitochondrial homeostasis by its effects on redox balance (Acuna 
Castroviejo et al., 2011). The melatonin receptors present in the plasma membrane have been 
shown to be important in restoring mitochondrial function (Dragicevic et al., 2011). Melatonin 
has been reported to uncouple oxidative phosphorylation by activation of UCP2 and UCP3 
thereby reducing ROS formation (Acuna-Castroviejo & Escames, unpublished data), which 
could contribute to the cardioprotection seen in hearts from the HFD melatonin-treated rats. It 
has become clear that, in view of melatonin’s actions on the mitochondria, further studies are 
needed to clarify the role of UCP3 in melatonin-induced cardioprotection. Particularly, the 
effect of melatonin treatment should also be studied under baseline conditions. 
 
Finally, the possibility that PGC1-α was involved in the cardioprotective actions of melatonin 
in the myocardium was also investigated. It has recently been shown that the beneficial effects 
of melatonin in improving cellular function and organism health directly or indirectly depend 
on activation of the sirtuin isoform, silent information regulator (SIRT) 1 (Cuesta S et al., 
2013). To identify whether the SIRT1/PGC1-α pathway mediates the observed mitochondrial 
protective effect of melatonin on hepatocytes, it was shown that blocking SIRT 1 activity 
reversed the protective effects of melatonin on cadmium mediated mitochondrial injury (Guo 
P et al., 2014). These data suggest that the effects of melatonin in promoting mitochondrial 
biogenesis and the amelioration of mitochondrial dysfunction are related to upregulation of the 
SIRT1 / PGC1-α pathway. Since the beneficial effects of melatonin could partially be abolished 
by luzindole, a melatonin receptor blocker, it was suggested that these receptors are involved 
in the SIRT 1/PGC1-α pathway. However in the present study, expression of PGC1-α (fig 3-
23) was similar in all four groups studied, suggesting that further studies are required to 
determine its role in melatonin-induced cardioprotection. 
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CHAPTER 5 
 
5.1 CONCLUSIONS 
 
Obesity has long been associated with insulin resistance and increased cardiovascular risk. In 
view of this, many researchers have attempted to elucidate the underlying mechanisms and 
relationships underpinning obesity to facilitate management and potential treatment thereof.  
The present study demonstrated that the HFD significantly increased body weight and visceral 
fat mass as well as elevated blood glucose and insulin levels, indicative of insulin resistance. 
Alterations in the lipid profile and adipokine secretions (leptin, adiponectin) are in agreement 
with most of the results obtained in previous studies of diet-induced obesity thus the HFD 
proved to be a useful model of diet-induced obesity with a more pronounced impact on 
biometric and metabolic changes compared to the DIO model. However, the HFD did not 
exacerbate the effects of I/R injury, as evidenced by the fact that the infarct sizes and functional 
recovery during reperfusion were similar to those of rats receiving normal rat chow. Plasma 
analysis also showed no evidence of lipid peroxidation. Similarly, the HFD had no effect on 
activation of the RISK and SAFE pathways under baseline conditions as well as after 10min 
of reperfusion following ischaemia. Similarly no increased activation was seen for AMPK and 
JNK during reperfusion while levels of UCP3 and PGC1-alpha (α) were not affected during 
reperfusion either. 
 
Since previous studies have shown melatonin to have beneficial effects in DIO, we investigated 
the effect of long-term oral administration on the HFD model. Melatonin treatment for 16 
weeks was associated with reductions in body weight and visceral fat mass associated with 
lower blood glucose levels. Melatonin lowered plasma leptin levels in HFD-fed animals while 
having no effect on the leptin concentration of control animals. Melatonin did not affect plasma 
adiponectin levels or the lipid profile in both control and HFD rats. Intracellular signaling in 
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the presence of melatonin was similar in both the control and HFD groups for the RISK and 
SAFE pathway kinases. 
Melatonin successfully reversed several of the changes due to obesity and significantly reduced 
myocardial infarct size. Unfortunately the experimental approach followed in this study did not 
shed more light on the mechanisms involved in melatonin-induced cardioprotection in obesity. 
 The study has a number of shortcomings which should be attended to: (i) the effect of 
melatonin on intracellular signaling should be evaluated under baseline conditions. Although 
this was done for PKB/Akt and ERK activation, the expression and activation of AMPK, JNK 
and STAT3, as well as the expression of UCP3 and PGC-1alpha should also have been studied 
under these conditions; (ii) the activation of the RISK and SAFE pathways should be studied 
in a larger series of animals, preferably at more and shorter reperfusion times.  
 
Future studies should also attempt to elucidate the mechanism whereby melatonin treatment 
protects the hearts from obese animals, with particular focus on the mitochondria permeability 
transition pore. Since the rats with HFD-induced obesity did not show overt signs of lipid 
peroxidation, the other effects of melatonin on intracellular signaling should be considered, 
also the contribution of its profound anti-adrenergic effects. 
However the anti-obesogenic and cardioprotective properties of melatonin were very 
significant indeed. Melatonin is a cheap drug with enormous clinical potential and may be of 
particular importance in a country such as the RSA with its high incidence of obesity and 
cardiovascular disease. Further studies, both clinical and experimental, are required to develop 
its full potential. 
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